Potent and selective inhibitors of the calcium-activated potassium channel KCa3.1 for use as platform therapeutics

JP2024503571A5Active Publication Date: 2024-11-14チャンディジョージ カニアンタラ +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023533238
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-30
Filing Date
2021-11-30
Publication Date
2024-11-14
Estimated Expiration
2041-11-30

AI Technical Summary

Technical Problem

Existing molecular inhibitors of the KCa3.1 potassium channel, such as TRAM-34 and NS6180, have poor oral bioavailability and pharmacokinetic properties, hindering their progression to clinical trials, while Senicapoc, although safe, has an expired patent.

Method used

Development of a series of phenyldihydropyridines with desirable properties, including oral bioavailability and good pharmacokinetic properties, as KCa3.1 inhibitors.

Benefits of technology

The phenyldihydropyridines exhibit high potency and selectivity for KCa3.1 channels, effectively inhibiting them and showing promise in treating various medical conditions associated with increased or altered KCa3.1 activity, including stroke.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Stroke, etc. Ca 3. Provided is the use of a compound of formula (I), as well as certain specific illustrative compounds, or a pharma- ceutically acceptable salt, solvate or derivative thereof, in the preparation of a medicament for treating or preventing a condition associated with increased or altered activity of 1.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for treating stroke, etc. Ca 3. The use of the compounds of formula (I), as well as certain specific compounds, or a pharma- ceutically acceptable salt, solvate or derivative thereof, in the preparation of a medicament for treating or preventing a condition associated with increased or altered activity of 1. [Background technology]

[0002] The listing or discussion of a prior-published document in this specification should not necessarily be taken as an acknowledgement that the document is part of the state of the art or is common general knowledge.

[0003] K is one of 78 potassium channel genes in the human genome. Ca 3.1 (KCNN4) encodes an intermediate conductance calcium-activated potassium channel (SP Alexander et al., Br. J. Pharmacol. 2017, 174 Suppl 1, S1-S16; GA Gutman et al., Pharmacol. Rev. 2005, 57, 473-508; LK Kaczmarek et al., Pharmacol. Rev. 2017, 69, 1-11; and AD Wei et al., Pharmacol. Rev. 2005, 57, 463-472). This channel is composed of four K Ca It is a complex of 3.1 subunits, each bound to calmodulin (CaM), which functions as a calcium sensor (Figure 1A). The cryo-EM structure of the complex has been determined, and the binding sites for inhibitors and activators have been determined by mutagenesis (Figure 1B). Ca 2+ activation K + Channel K Ca3.1 functions as a cation counterbalancer that maintains calcium influx and calcium signaling in immune cells (lymphocytes, microglia, macrophages, mast cells), red blood cells, platelets, epithelial cells of the lung and gastrointestinal tract, endothelial cells, fibroblasts, myofibroblasts, and some cancers. In these cells, external signals activate the relevant cell surface receptors, resulting in the release of intracellular Ca 2+ This causes an increase in K Ca Open the 3.1 channel (Figure 2).

[0004] Pharmacological and genetic studies have demonstrated that K Ca 3.1 was validated as a therapeutic target. Ca K3.1 inhibitors reduce vascular narrowing and atherosclerosis in rodent and porcine models (D. Tharp et al., Arterioscler Thromb. Vasc. Biol. 2008, 28, 1084-1089; K. Toyama et al., J. Clin. Invest. 2008, 118, 3025-3037; R. Kohler et al., Circulation 2003, 108, 1119-1125). CaBlockade of 3.1 is a genetic factor in KCa3.1, including inflammatory bowel disease (L. Di et al., Proc. Natl. Acad. Sci. USA 2010, 107, 1541-1546; D. Strobaek et al., Br. J. Pharmacol. 2013, 168, 432-444; S. Ohya et al., Am. J. Physiol. Gastrointest. Liver Physiol. 2014, 306, G873-885), multiple sclerosis (E. Reich et al., Eur. J. Immunol. 2005, 35, 1027-1036), glomerulonephritis (H. Kang et al., Cell Rep. 2014, 8, 1210-1224), inflammatory arthritis (H. Kang et al., Cell Rep. 2014, 8, 1210-1224), bone resorption (H. Kang et al., Cell Rep. 2014, 8, 1210-1224), algic rhinitis (H. Lin et al., Sci. Rep. 2015, 5, 13127; H. Lin et al., Int. Immunopharmacol. 2014, 23, 642-648), conjunctival and corneal fasciitis (H. Yang et al., Exp Eye Res 2013, 110, 76-87; G. Anumanthan et al., PLoS One 2018, 13), myofasciitis (L. Zhao et al., Pflugers Arch. 2015, 467, 2275-2285; L. Wang et al., Pflugers Arch. 2016, 468, 2041-2051), pulmonary neuropathy (D. Amrutkar Experimental Biology Meeting 2021; L. Organ et al., Am. J. Respir. Cell Mol. Biol. 2017, 56, 539-550; L. Organ et al., Am. J. Respir. Cell Mol. Biol. 2017, 56, 539-550; U. Perera et al., Can. Respir. J. 2021, 6683, 1955), diabetic nephropathy (C. Huang et al., Diabetes 2013, 62, 2923-2934; C. Huang et al., PLoS One 2018, 13, e0192800; I. Grgic et al., Proc. Natl. Acad. Sci. USA 2009, 106, 14518-14523; C. Huang et al., Nephrology Dialysis Transplantation 2014, 29(2), 313-324; C. Huang et al., Sci. Rep. 2016, 6, 23884), diet-induced hepatic steatosis, nonalcoholic steatosis, and hepatic fibrosis (L. Paka et al., World J. Gastroenterol. 2017, 23, 4181-4190; C. Freise and U. Querfeld. Pharmacol. Res. 2014, 85, 6-14), and sickle cell disease (L. De Franceschi et al., J. Clin. Invest. 1994, 93, 1670-1676; J. Stocker et al., Blood 2003, 101(6), 2412-8; K. Ataga et al., Pharmacotherapy 2006, 26, 1557-1564;K. Ataga et al., Blood 2008, 111(8), 3991-7;K. Ataga et al., Expert. Opin. Investig. Drugs 2009, 8(2),231-9;K. Ataga et al., Br J Haematol. 2011, 153(1), 92-104; K. Ataga et al., Br J Haematol. 2021, 192(5), e129-e132) improves disease in rodent models. In the nervous system, K. Ca3.1 regulates microglial activation, and channel inhibitors have been shown to be effective in treating stroke (Y. Chen et al., J. Cereb. Blood Flow Metab. 2011, 31, 2363-2374;Y. Chen et al., J. Cereb. Blood Flow Metab. 2016, 36, 2146-2161;M. Yi et al., J. Neuroinflammation 2017, 14, 203), Alzheimer's disease (M. Yi et al., Mol. Cell Neurosci. 2016, 76, 21-32;T. Wei et al., Front. Pharmacol. 2016, 7, 528;L. Jin et al., Ann. Clin. Transl. Neurol. 2019, 6, 723-738), Parkinson's disease (J. Lu et al., J. Neuroinflammation 2019, 16, 273) and traumatic brain injury (F. Mauler et al., Eur. J. Neurosci. 2004, 20, 1761-1768;K. Urbahns et al., Bioorg. Med. Chem. Lett. 2005, 15, 401-404;K. Urbahns et al., Bioorg. Med. Chem. Lett. 2003, 13, 2637-2639). Ca 3.1 Blockers treat pulmonary fibrosis in rodent and sheep models, myocardial fibrosis in rodent models, and renal fibrosis in rodent models via inhibition of myofibroblasts (L. Organ et al., Am. J. Respir. Cell Mol. Biol. 2017, 56, 539-550; L. Organ et al., Am. J. Respir. Cell Mol. Biol. 2017, 56, 539-550; U. Perera et al. Can. Respir. J. 2021, 6683, 1955;L. Zhao et al., Pflugers Arch. 2015, 467, 2275-2285;L. Wang et al., Pflugers Arch. 2016, 468, 2041-2051;C. Huang et al., Diabetes 2013, 62, 2923-2934; C. Huang et al., PLoS One 2018, 13, e0192800; I. Grgic et al., Proc. Natl. Acad. Sci. USA 2009, 106, 14518-14523; C. Huang et al., Nephrology Dialysis Transplantation 2014, 29(2), 313-324; C. Huang et al., Sci. Rep. 2016, 6, 23884). The shortened survival time of patients with malignant gliomas is due to the presence of intratumoral K Ca 3.1 expression is associated with increased K Ca 3.1 inhibitors reduce tumor invasiveness in rodent xenograft models (G. D'Alessandro et al., Cell Death Dis. 2013, 4, e773; A. Grimaldi et al., Cell Death Dis. 2016, 7, e2174; K. Turner et al., Glia 2014, 62, 971-981; G. D'Alessandro et al., Oncotarget 2016, 7, 30781-30796). Genetic and pharmacological studies have also shown that K Ca3.1 is the liver (P. Song et al., J. Cancer 2017, 8, 1568-1578), ovary (Z. Wang et al., Oncogene 2007, 26, 5107-5114), colon (N. Sassi et al., Biochim. Biophys. Acta. 2010, 1797(6-7), 1260-7; U. De Marchi et al., Cell Calcium 2009, 45(5), 509-16), rectum (H. Xu et al., BMC Cancer 2014, 10(14), 330; W. Lai et al., Med. Oncol. 2013, 30(2),566); 2011, 26(4), 909-17), pancreatic (H. Jaeger et al., Mol. Pharmacol. 2004, 65(3), 630-638) and leukaemia (E. Groessinger et al., Leukemia 2014, 28, 954-958). Another possible indication is hereditary xerocytosis, an autosomal dominant congenital hemolytic anemia characterized by cation leakage of the red cell membrane, accompanied by water loss, reduced potassium content, and altered hematological parameters, in which affected red blood cells (RBCs) are resistant to erythrocytosis (I. Andolfo et al., Am. J. Hematol. 2015, 90, 921-926; E. Fermo et al., Sci. Rep. 2017, 7, 1744; R. Rapetti-Mauss et al., Haematologica 2017, 102, e415-e418; R. Rapetti-Mauss et al., Haematologica 2016, 101, e431-e435; and A. Rivera et al., Am. J. Physiol. Cell Physiol. 2019, 317, C287-C302). In a subset of these patients, gain-of-function mutations of K Ca3.1 cause a loss of KCl and water, leading to red blood cell shrinkage and anemia (E. Fermo et al., Sci. Rep. 2017, 7, 1744; A. Rivera et al., Am. J. Physiol. Cell Physiol. 2019, 317, C287-C302). Therefore, K Ca 3.1 Blockers are predicted to reverse these changes and improve hematological parameters (R. Rapetti-Mauss et al., Haematologica 2016, 101, e431-e435). Ca Pharmacological blockade of 3.1 has already been shown to improve hematological parameters in animal models and humans with sickle cell anemia by preventing KCl and water loss and decreasing red blood cell shrinkage (J. Stocker et al., Blood 2003, 101(6), 2412-8; K. Ataga et al., Blood 2008, 111(8), 3991-7; K. Ataga et al., Expert. Opin. Investig. Drugs 2009, 8(2),231-9; K. Ataga et al., Br J Haematol. 2011, 153(1), 92-104; K. Ataga et al., Br J Haematol. 2021, 192(5), e129-e132; C. Brugnara et al., J. Clin. Invest. 1993, 92(1), 520-6; S. Alper et al., Blood Cells Mol. Dis. 2009, 41(1), 22-34). K CaOther potential indications for 3.1 inhibitors, based on experimental studies in animal models, include asthma (Z. Yu et al., Front. Pharmacol. 2017, 8, 559;L. Chachi et al., J Immunol 2013, 191, 2624-2636;J. Der Velden et al., PLoS One 2013, 8, e66886;ZH. Yu et al., Am. J. Respir. Cell. Mol. Biol. 2013, 48(6), 685-93;D. Hynes et al., Steroids 2019, 19, 151, 108459;P. Girodet et al., Am. J. Respir. Cell Mol. Biol. 2013, 48(2), 212-9;https: / / ichgcp.net / clinical-trials-registry / NCT00861185), allergic rhinitis (H. Lin et al., Sci. Rep. 2015, 5, 13127), secretory diarrhea (P. Rufo et al., J. Clin. Invest. 1997, 100, 3111-3120) and cystic fibrosis (A. Philp et al., Sci. Rep. 2018, 8, 9320).

[0005] However, TRAM-34, NS6180, 4-phenyl-4-pyran, cyclohexadiene, etc. Ca Molecular inhibitors of 3.1 have not progressed to clinical trials due to poor oral bioavailability and pharmacokinetic properties, whereas Senicapoc (ICA-17043) has progressed to clinical trials and has been shown to be safe, but is off patent. Summary of the Invention [Problem to be solved by the invention]

[0006] Thus, it is an orally bioavailable, potent and selective K Ca 3.1 Inhibitors need to be discovered. [Means for solving the problem]

[0007] Summary of the invention It has now been surprisingly found that a series of phenyldihydropyridines exhibit desirable properties.Aspects and embodiments of the invention will now be described with reference to the following numbered clauses.

[0008] 1. Formula (I): [ka] [In the formula, R1 is selected from H, halo, CF3, CN or NO2; R2 and R3 are independently selected from H, halo, CH3, CF3, CN, or NO2; R4 is selected from H, halo, CN or CF3; R5 and R6 are independently R 9a C(O)O-, R 9b OC(O)-, R 9c C(O)NRd-, R 9e R 9f NC(O)-, or an alkyl ketone having 1 to 10 carbon atoms, wherein the carbon atoms are branched or unbranched and unsubstituted or substituted with one or more substituents selected from halo and NO2; R7 and R8 are independently H, NR 10a R 10b , OR 10c or C1-C3 alkyl, unsubstituted or substituted with one or more substituents selected from halo; One of the pairs of R5 and R7 or R6 and R8, together with the carbon atom to which they are attached, is carbocyclic or heterocyclic and is unsubstituted or selected from halo, =O, -OC(O)R 10d , -(O)COR 10e and forming a 4-14 membered ring system substituted with one or more substituents selected from C1-C6 alkyl; R 9a ~R 9f and R 10a ~R 10eare independently selected from H, and C1-C6 alkyl that is unsubstituted or substituted with one or more substituents selected from halo. or a pharma- ceutically acceptable salt and / or solvate thereof.

[0009] 2. The compound according to clause 1, wherein R1 is selected from H, F, Cl, Br, CF3 or NO2.

[0010] 3. The compound according to clause 1 or clause 2, wherein R2 and R3 are independently selected from H, F, Cl, Br, CH3, CF3 or NO2.

[0011] 4. A compound according to any one of the preceding clauses, wherein R4 is selected from H, F, Cl, Br, or CF3.

[0012] 5. R5 and R6 are independently R 9a C(O)O-, R 9b A compound according to any one of the preceding clauses, selected from OC(O)-, or an alkyl ketone having 1 to 10 carbon atoms, wherein the carbon atoms are branched or unbranched and unsubstituted or substituted with one or more substituents selected from Cl, F, and NO2.

[0013] 6. R7 and R8 are independently selected from H, or C1-C3 alkyl, unsubstituted or substituted with one or more substituents selected from F and Cl; or A compound according to any one of the preceding clauses, wherein one of the pairs of R5 and R7 or R6 and R8, together with the carbon atom to which they are attached, forms a 4-10 membered ring system that is carbocyclic or heterocyclic and is unsubstituted or substituted with one or more substituents selected from F, Cl, =O, and C1-C6 alkyl.

[0014] 7.R 9a ~R 9f and R 10a ~R 10eis independently selected from H, and C1-C3 alkyl that is unsubstituted or substituted with one or more substituents selected from F and Cl.

[0015] 8. R1 is selected from H, F, Cl, or CF3; R2 and R3 are independently selected from H, F, Cl, or CF3; R4 is selected from H, F, Cl, or CF3; R5 and R6 are independently R 9b OC(O)-, selected from alkyl ketones having 1 to 3 carbon atoms, the carbon atoms being unsubstituted or substituted with one or more substituents selected from Cl and F; The compound according to any one of the preceding clauses, wherein R7 and R8 are independently selected from H, or methyl that is unsubstituted or substituted with one or more substituents selected from F and Cl.

[0016] 9. R1 is selected from H, F, or Cl; and / or R2 is selected from CF3, or in particular H or F; and / or R3 is selected from H or CF3; and / or R4 is H; and / or R5 and R6 are independently CH3OC(O)- or propan-2-onyl (e.g., R5 and R6 are both CH3OC(O)-); and / or A compound according to any one of the preceding clauses, wherein R7 and R8 are independently selected from H and CH3.

[0017] 10. A compound according to any one of the preceding clauses, wherein at least one of R7 and R8 is H.

[0018] 11. A compound according to any one of the preceding clauses, wherein both R7 and R8 are H.

[0019] 12. The compound according to any one of clauses 1-10, wherein R7 is H and R8 is CH3.

[0020] 13. The compound according to any one of clauses 1-10, wherein R7 and R8 are both CH3.

[0021] 14. The compound according to any one of clauses 1-10, wherein R7 is CH3 and R8 is H.

[0022] 15. The following list: [Table 1] [Table 2] or a salt or solvate thereof. 16. The following list: [Table 3] [Table 4] or a salt or solvate thereof. 17. The following list: [Table 5] or a salt or solvate thereof.

[0023] 18. The following list: [Table 6] or salts and solvates thereof.

[0024] 19. A compound: [ka] or salts and solvates thereof.

[0025] 20. A pharmaceutical composition comprising a compound of formula (I) as defined in any one of clauses 1 to 19, or a salt or solvate thereof, in combination with a pharma- ceutically acceptable carrier, adjuvant or vehicle.

[0026] 21. A compound of formula (I) or a salt or solvate thereof as defined in any one of clauses 1 to 19 for use in medicine.

[0027] 22.K Ca 3. A compound of formula (I) as defined in any one of clauses 1 to 19, or a salt or solvate thereof, for use in the treatment or prevention of a condition associated with an increase or altered activity of 1.

[0028] 23.K Ca 3. A compound of formula (I) as defined in any one of clauses 1 to 19, or a salt or solvate thereof, for use in the manufacture of a medicament for the treatment or prevention of a condition associated with an increase or altered activity of 1.

[0029] 24.K Ca 3. A method for the treatment or prevention of a condition associated with an increase or altered activity of 1, comprising administering to a patient in need thereof an effective amount of a compound of formula (I) or salts and solvates thereof as defined in any one of clauses 1 to 19.

[0030] 25.K Ca3.1 is associated with an increase or altered activity of leukemia or, in particular, inflammatory bowel disease (IBD), fibrotic diseases (lung, liver, kidney, heart, conjunctiva, cornea), nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), glioma (glioblastoma), lung cancer, pancreatic cancer, hepatocellular carcinoma, ovarian cancer, colorectal cancer, cystic fibrosis, diabetic kidney disease, glomerulonephritis, bone resorption, inflammatory arthritis, multiple sclerosis, atherosclerosis, restenosis after angioplasty, in-stent neoatherosclerosis, stroke, traumatic brain injury, Alzheimer's disease, hereditary sclerocytosis, sickle cell anemia, asthma, allergic rhinitis, microglial activation, nitric oxide-dependent neurodegeneration, neuro-oncological diseases, and orphan red blood cell disorders. 20. A compound for the use according to clause 19, the use according to clause 20 or the method according to clause 21, selected from one or more of the following:

[0031] 26.K Ca 3. The compound for use or method according to clause 25, wherein the condition associated with an increase or altered activity of 1 is selected from leukemia or, in particular, one or more of inflammatory bowel disease (IBD), fibrotic disease (lung, liver, kidney, heart, conjunctiva, cornea), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), glioma (glioblastoma), lung cancer, pancreatic cancer, hepatocellular carcinoma, ovarian cancer, colorectal cancer, cystic fibrosis, diabetic kidney disease, glomerulonephritis, bone resorption, inflammatory arthritis, multiple sclerosis, atherosclerosis, restenosis after angioplasty, in-stent neoatherosclerosis, stroke, traumatic brain injury, Alzheimer's disease, hereditary sicca, sickle cell anemia, asthma, allergic rhinitis, microglial activation and nitric oxide-dependent neurodegeneration.

[0032] 27. The compound for use or method according to clause 26, wherein the condition is stroke. [Brief description of the drawings]

[0033] [Figure 1] Figure 1 shows: (A) Each KCa3.1 subunit contains six transmembrane segments, with the loop between segments 5 and 6 forming the pore. The cytoplasmic C-terminus constitutively binds CaM (CM Fanger et al., J Biol Chem 1999, 274, 5746-5754). Four KCa3.1 subunits and four CaMs form a functional channel. Figure adapted from H. Wulff & NA Castle, Expert Rev. Clin. Pharmacol. 2010, 3, 385-396; and (B) the cryo-EM structure of the KCa3.1-CaM complex. Binding sites for blockers are indicated. Peptide inhibitors bind to the outer mouth of the channel. Small molecule inhibitors bind to the inner pore or to the window region of the inner pore. Small molecule activators bind to the inner surface of the KCa3.1-CaM complex. Figure adapted from BM Brown et al., Annu. Rev. Pharmacol. Toxicol. 2020, 60, 219-240. [Diagram 2]Figure 2 shows the physiological role of KCa3.1. (A) shows that KCa3.1 plays an important physiological role in immune cells (microglia, T cells, B cells, mast cells, monocytes, macrophages), red blood cells, platelets, epithelial cells of the lung and digestive tract, endothelial cells, fibroblasts, myofibroblasts and some cancers. In these cells, external signals activate the relevant cell surface receptors, causing an increase in intracellular Ca2+, opening the KCa3.1 channel. This channel functions as a cation counterbalancer to maintain calcium signaling. Figure taken from Wulff & NA Castle, Expert Rev. Clin. Pharmacol. 2010, 3, 385-396; (B) shows that many cell types can differentiate into protomyofibroblasts. Upon stimulation by transforming growth factor beta (TGF-b), platelet-derived growth factor (PDGF), epidermal growth factor (EGF), fibronectin, mechanical tension, etc., primary myofibroblasts differentiate into myofibroblasts that contribute to the profibrotic effects in fibrosis of many organs. Myofibroblasts upregulate the expression of KCa3.1, and its inhibition suppresses myofibroblast proliferation and profibrotic effects. Figure taken from S.W.M. van der Borne et al., Nat. Rev. Cardiol. 2010, 7, 30-37; and (C) KCa3.1 plays a key role in proinflammatory microglia that contributes to neuroinflammatory diseases such as stroke, Alzheimer's disease, Parkinson's disease, and traumatic brain injury. KCa3.1 is upregulated as microglia differentiate into M1 proinflammatory cells, and blockade of the channel suppresses the production of neuroinflammatory mediators such as IL-1β, IL-6, and TNF-α. In contrast, KCa3.1 is downregulated when microglia differentiate into M2 anti-inflammatory cells. Thus, KCa3.1 inhibitors preferentially target proinflammatory microglia. Figure adapted from SR Roig et al., J. Neurol. Neuromed. 2018, 3, 18-23. [Diagram 3]3 shows the effect of exemplary compounds of groups 2-4 on KCa3.11 currents. Concentration response curves of exemplary compounds are shown. [Figure 4] FIG. 4 shows the pharmacophores for potent blockade of KCa3.1 and >1000-fold higher selectivity over CaV1.2 (Group 4c). [Diagram 5] FIG. 5 shows the selectivity of compound 103 (tested at 3 μM) against a panel of other molecular targets (Eurofins Pharmacological P9 Diversity Panel Safety Screen). [Figure 6] FIG. 6 shows the pharmacokinetic evaluation of compound 103 (Group 4c) in rats after a single intravenous injection (5 mg / kg) or oral administration (50 mg / kg). [Figure 7] FIG. 7 shows the histopathological analysis. [Figure 8] Figure 8 shows that (A) in rats subjected to 60 min rat middle cerebral artery occlusion (MCAO) with 7 days of reperfusion, Compound 103 effectively reduced infarct volume compared to vehicle control (n=28) and was more effective than the positive control edaravone; and (B) the neurological behavior scores measured at 48 hours (n=8) and 7 days (n=5) were improved more effectively than edaravone. Data represent mean ± SEM, and statistical significance was analyzed by one-way ANOVA (A) or two-way ANOVA (B); *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. [Figure 9] Figure 9 shows that Compound 103 (10 mg / kg) effectively reduced Iba1+CD11b+ double positive activated microglia in CA1, CPu, M1 and S1 brain regions on day 7 compared with MCAO or vehicle groups. Data represent mean ± SEM and statistical significance was analyzed by one-way ANOVA; *p<0.05, n=5. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0034] explanation As mentioned above, it has been surprisingly found that a series of phenyldihydropyridines exhibit unexpectedly good properties that overcome one or more of the problems previously identified. Thus, a first aspect of the present invention provides a compound having the formula (I): [ka] [In the formula, R1 is selected from H, halo, CF3, CN or NO2; R2 and R3 are independently selected from H, halo, CH3, CF3, CN, or NO2; R4 is selected from H, halo, CN or CF3; R5 and R6 are independently R 9a C(O)O-, R 9b OC(O)-, R 9c C(O)NRd-, R 9e R 9f NC(O)-, or an alkyl ketone having 1 to 10 carbon atoms, wherein the carbon atoms are branched or unbranched and unsubstituted or substituted with one or more substituents selected from halo and NO2; R7 and R8 are independently H, NR 10a R 10b , OR 10c or C1-C3 alkyl, unsubstituted or substituted with one or more substituents selected from halo; One of the pairs of R5 and R7 or R6 and R8, together with the carbon atom to which they are attached, is carbocyclic or heterocyclic and is unsubstituted or selected from halo, =O, -OC(O)R 10d , -(O)COR 10e and forming a 4-14 membered ring system substituted with one or more substituents selected from C1-C6 alkyl; R 9a ~R 9f and R 10a ~R 10e are independently selected from H, and C1-C6 alkyl that is unsubstituted or substituted with one or more substituents selected from halo. or a pharma- ceutically acceptable salt and / or solvate thereof.

[0035] The term "comprising" referred to herein may be interpreted as requiring the recited features, but not limiting the presence of other features. Alternatively, the word "comprising" may relate to a situation in which only the listed components / functions are intended to be present (e.g., the word "comprising" may be replaced with the phrase "consisting of" or "consisting essentially of"). It is expressly contemplated that both broader and narrower interpretations may be applied to all aspects and embodiments of the present invention. In other words, the word "comprising" and its synonyms may be replaced with the phrase "consisting of" or the phrase "consisting essentially of" or its synonyms, and vice versa.

[0036] The phrase "consisting essentially of" and its synonyms may be construed herein to indicate a material that may have trace amounts of impurities present. For example, the material may be 90% or greater pure, e.g., greater than 9.5% pure, e.g., greater than 97% pure, e.g., greater than 99% pure, e.g., greater than 99.9% pure, e.g., greater than 99.999% pure, e.g., 100% pure, etc.

[0037] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0038] A reference herein (in any aspect or embodiment of the invention) to a compound of formula (I) includes a reference to such a compound per se, a tautomer of such a compound, and also a pharma- ceutically acceptable salt or solvate, or a pharma- ceutically functional derivative of such a compound.

[0039] Pharmaceutically acceptable salts include acid addition salts and base addition salts.Such salts can be formed by conventional means, for example, by reacting the free acid or free base form of the compound of formula (I) with one or more equivalents of a suitable acid or base, optionally in a solvent or medium, and if the salt is insoluble, remove the solvent or medium using standard techniques (for example, vacuum, lyophilization or filtration).Salts can also be prepared by exchanging the counterion of the compound of formula (I) in the form of a salt with another counterion, for example, using a suitable ion exchange resin.

[0040] Examples of pharma- ceutically acceptable salts include acid addition salts derived from mineral and organic acids, and salts derived from metals such as sodium, magnesium, or preferably potassium and calcium.

[0041] Examples of acid addition salts include acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, arylsulfonic acids (e.g., benzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, p-toluenesulfonic acid), ascorbic acid (e.g., arsacorbic acid), L-aspartic acid, benzoic acid, 4-acetamidobenzoic acid, butanoic acid, (+)-camphoric acid, camphorsulfonic acid, and the like. Phobic acid, (+)-(1S)-camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid (e.g., D-gluconic acid), glucuronic acid (e.g., D-gluconic acid), uronic acid), glutamic acid (e.g., L-glutamic acid), α-oxoglutaric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, isethionic acid, lactic acid (e.g., (+)-L-lactic acid and (±)-DL-lactic acid), lactobionic acid, maleic acid, malic acid (e.g., (-)-L-malic acid), malonic acid, (±)-DL-mandelic acid, metaphosphoric acid, methanesulfonic acid, 1 Examples of acid addition salts include those formed with -hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, propionic acid, L-pyroglutamic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, tartaric acid (e.g., (+)-L-tartaric acid), thiocyanic acid, undecylenic acid, and valeric acid.

[0042] Particular examples of salts are salts derived from mineral acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid and sulfuric acid; organic acids such as tartaric acid, acetic acid, citric acid, malic acid, lactic acid, fumaric acid, benzoic acid, glycolic acid, gluconic acid, succinic acid, arylsulfonic acid; and metals such as sodium, magnesium, or, preferably, potassium and calcium.

[0043] As mentioned above, any solvates of the compounds and their salts are also encompassed by formula I. Preferred solvates are those formed by the incorporation of molecules of non-toxic pharma- ceutically acceptable solvents (hereinafter referred to as solvating solvents) into the solid-state structure (e.g., crystalline structure) of the compounds of the present invention. Examples of such solvents include water, alcohols (e.g., ethanol, isopropanol, butanol, etc.) and dimethylsulfoxide. Solvates can be prepared by recrystallizing the compounds of the present invention using a solvent or a mixture of solvents containing a solvating solvent. In any case, whether a solvate is formed can be determined by analyzing the crystals of the compound using well-known standard techniques such as thermogravimetric analysis (TGE), differential scanning calorimetry (DSC), and X-ray crystallography.

[0044] The solvates may be stoichiometric or non-stoichiometric solvates. Particularly preferred solvates are hydrates, examples of which include hemihydrates, monohydrates and dihydrates.

[0045] For a more detailed description of solvates and methods used to make and characterize them, see Bryn et al., Solid-State Chemistry of Drugs, Second Edition, published by SSCI, Inc of West Lafayette, IN, USA, 1999, ISBN 0-967-06710-3.

[0046] "Pharmaceutically functional derivatives" of compounds of formula (I) as defined herein include ester derivatives and / or derivatives that have or provide the same biological function and / or activity as any relevant compound of the present invention. Thus, for purposes of the present invention, the term also includes prodrugs of compounds of formula (I).

[0047] The term "prodrug" of related compounds of formula (I) includes any compound that, following oral or parenteral administration, is metabolized in vivo to form the compound in experimentally detectable amounts and within a given time period (e.g., within a dosing interval of between 6 and 24 hours (i.e., 1 to 4 times daily)).

[0048] Prodrugs of compounds of formula (I) can be prepared by modifying functional groups present on the compounds in such a way that the modifications are cleaved in vivo when such prodrugs are administered to a mammalian subject. The modifications are usually achieved by synthesizing the parent compound with a prodrug substituent. Prodrugs include compounds of formula (I) in which a hydroxyl, amino, sulfhydryl, carboxyl or carbonyl group in the compounds of formula (I) is bonded to any group that can be cleaved in vivo to regenerate a free hydroxyl, amino, sulfhydryl, carboxyl or carbonyl group, respectively.

[0049] Examples of prodrugs include, but are not limited to, esters and carbamates of hydroxyl functional groups, ester groups of carboxyl functional groups, N-acyl derivatives and N-Mannich bases. General information on prodrugs can be found, for example, in Bundegaard, H. "Design of Prodrugs" p. I-92, Elsevier, New York-Oxford (1985).

[0050] The compounds of formula (I), as well as the pharma- ceutically acceptable salts, solvates and pharma- ceutically functional derivatives of such compounds, are hereinafter collectively referred to as "compounds of formula (I)."

[0051] Compounds of formula (I) may contain double bonds and therefore may exist as E (entgegen) and Z (zusammen) geometric isomers about each double bond, and all such isomers and mixtures thereof are included within the scope of the present invention.

[0052] Compounds of formula (I) may exist as positional isomers and may also exhibit tautomerism, all tautomers and mixtures thereof are included within the scope of the present invention.

[0053] The compounds of formula (I) may contain one or more asymmetric carbon atoms and therefore may exhibit optical isomerism and / or diastereoisomerism, the diastereomers of which may be separated using conventional techniques, such as, for example, chromatography or fractional crystallization. The various stereoisomers may be isolated by separating racemates or other mixtures of the compounds using conventional techniques, such as, for example, fractional crystallization or HPLC. Alternatively, the desired optical isomers may be prepared by reacting the appropriate optically active starting materials under conditions that do not cause racemization or epimerization (i.e., the "chiral pool" method), by derivatization (i.e., resolution, including dynamic resolution), for example, by reaction with a homochiral acid followed by separation of the diastereomeric derivatives by conventional means, such as chromatography, by a "chiral auxiliary" which may then be removed at a suitable stage, or by reaction with a suitable chiral reagent or chiral catalyst, all under conditions known to those skilled in the art. All stereoisomers and mixtures thereof are included within the scope of the present invention.

[0054] For the avoidance of doubt, in the context of the present invention, the term "treatment" includes reference to the curative or palliative treatment of patients in need of such treatment, as well as to the prophylactic treatment and / or diagnosis of patients susceptible to the relevant pathology.

[0055] The terms "patient" and "patients" include reference to a mammalian (such as a human) patient. As used herein, the terms "subject" or "patient" are well-recognized in the art and are used interchangeably herein to refer to a mammal, including dogs, cats, rats, mice, monkeys, cows, horses, goats, sheep, pigs, camels, and most preferably humans. In some embodiments, the subject is a subject in need of treatment or a subject having a disease or disorder. However, in other embodiments, the subject may be a normal subject. The term does not denote a particular age or sex. Thus, it includes adults and newborns, males or females.

[0056] The term "effective amount" refers to an amount of a compound that confers a therapeutic effect on the treated patient (e.g., an amount sufficient to treat or prevent a disease). The effect can be objective (i.e., measurable by some test or marker) or subjective (i.e., the subject sees or feels an effect).

[0057] The term "halo," as used herein, includes references to fluoro, chloro, bromo and iodo.

[0058] As used herein, when a 4-14 membered ring system is referred to herein as being carbocyclic or heterocyclic, it may contain 1-3 rings. For the avoidance of doubt, the carbocyclic or heterocyclic 4-14 membered ring system referred to herein may be formed partially using atoms that are already part of the ring, but this should not be counted in the total number of rings in the 4-14 membered ring system. The 4-14 membered ring system may be a 6-10 membered ring system, for example a 6-8 membered ring system, and may be monocyclic or bicyclic.

[0059] Unless otherwise specified herein, the term "aryl" as used herein includes any of the following: 6-14 (C 6-10Such groups are monocyclic, bicyclic, or tricyclic and have 6 to 14 ring carbon atoms, with at least one ring being aromatic. The point of attachment of the aryl group may be through any atom in the ring system. However, when aryl groups are bicyclic or tricyclic, they are attached to the remainder of the molecule through an aromatic ring. C 6-1 4Aryl groups include phenyl, naphthyl, etc., for example, 1,2,3,4-tetrahydronaphthyl, indanyl, indenyl, fluorenyl, etc. Embodiments of the invention include those where aryl is phenyl.

[0060] Unless otherwise stated in this specification, the term "alkyl" refers to a hydrocarbyl radical that is unbranched or branched, acyclic or cyclic, saturated or unsaturated (thus forming, for example, an alkenyl or alkynyl), and may be substituted or unsubstituted (for example, with one or more halo atoms). When the term "alkyl" refers to an acyclic group, it is preferably a C 1-10 alkyl, more preferably C 1-6 Alkyl (e.g., ethyl, propyl, (e.g., n-propyl or isopropyl), butyl (e.g., branched or unbranched butyl), pentyl, or, more preferably, methyl). When the term "alkyl" is a cyclic group (sometimes specified as the group "cycloalkyl"), it is preferably C 3-12 Cycloalkyl, more preferably C 5-10 (For example, C 5-7 ) cycloalkyl.

[0061] Unless otherwise stated in this specification, a "heterocyclic ring system" may be a 4-14 membered, e.g., 5-10 membered (e.g., 6-10 membered), heterocyclic group (i.e., a heteroaryl group) which may be aromatic, fully saturated or partially unsaturated, contains one or more heteroatoms selected from O, S, and N, and may contain one or two rings. Examples of heterocyclic ring systems referred to herein include azetidinyl, dihydrofuranyl (e.g., 2,3-dihydrofuranyl, 2,5-dihydrofuranyl), dihydropyranyl (e.g., 3,4-dihydropyranyl, 3,6-dihydropyranyl), 4,5-dihydro-1H-maleimido, dioxanyl, dioxolanyl, furanyl, furazanyl, hexahydropyrimidinyl, hydantoinyl, imidazolyl, isothiaziolyl, isoxazolidinyl, isoxazolyl, morpholinyl, 1,2- or 1,3-oxazinanyl, oxazolidinyl, oxazolyl, piperidinyl, piperazinyl, pyranyl, pyrazinyl, pyridazinyl, and the like. Examples of aryl include, but are not limited to, nyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrrolinyl (e.g., 3-pyrrolinyl), pyrrolyl, pyrrolidinyl, pyrrolidinonyl, 3-sulfonyl, sulfolanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl (e.g., 3,4,5,6-tetrahydropyridinyl), 1,2,3,4-tetrahydropyrimidinyl, 3,4,5,6-tetrahydropyrimidinyl, tetrahydrothiophenyl, tetramethylene sulfoxide, tetrazolyl, thiadiazolyl, thiazolyl, thiazolidinyl, thienyl, thiophenethyl, triazolyl, and triazinanyl.

[0062] Unless otherwise stated herein, a "carbocyclic ring system" may be 4-14 membered, e.g., 5-10 membered (e.g., 6-10 membered, e.g., 6 or 10 membered), and the carbocyclic group may be aromatic, fully saturated or partially unsaturated, and may contain one or two rings. Examples of carbocyclic ring systems mentioned herein include, but are not limited to, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, phenyl, naphthyl, decalinyl, tetralinyl, bicyclo[4.2.0]octanyl, and 2,3,3a,4,5,6,7,7a-octahydro-1H-indanyl. Particularly preferred carbocyclic groups include phenyl, cyclohexyl, and naphthyl.

[0063] The term "heteroaryl" as used herein denotes an aromatic group containing one or more heteroatoms (e.g., 1-4 heteroatoms), preferably selected from N, O and S (e.g., forming a monocyclic, bicyclic or tricyclic heteroaromatic group). Heteroaryl groups include those having 5-14 (e.g., 10) members and may be monocyclic, bicyclic or tricyclic, provided that at least one of the rings is aromatic. However, when heteroaryl groups are bicyclic or tricyclic, they are attached to the remainder of the molecule via an aromatic ring.Heterocyclic groups which may be mentioned are benzothiadiazolyl (including 2,1,3-benzothiadiazolyl), isothiochromanyl and more preferably acridinyl, benzimidazolyl, benzodioxanyl, benzodioxepinyl, benzodioxolyl (including 1,3-benzodioxolyl), benzofuranyl, benzofurazanyl, benzothiazolyl, benzoxadiazolyl (including 2,1,3-benzoxadiazolyl), benzoxazinyl (including 3,4-dihydro-2H-1,4-benzoxazinyl). ), benzoxazolyl, benzomorpholinyl, benzoselenadiazolyl (including 2,1,3-benzoselenadiazolyl), benzothienyl, carbazolyl, chromanyl, cinnolinyl, furanyl, imidazolyl, imidazo[1,2-a]pyridyl, indazolyl, indolinyl, indolyl, isobenzofuranyl, isochromanyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiaziolyl, isoxazolyl, naphthyridinyl (1,6-naphthyridinyl, or preferably 1,5-naphthyridinyl), nyl and 1,8-naphthyridinyl), oxadiazolyl (including 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl and 1,3,4-oxadiazolyl), oxazolyl, phenazinyl, phenothiazinyl, phthalazinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinolizinyl, quinoxalinyl, tetrahydroisoquinolinyl (including 1,2,3,4-tetrahydroisoquinolinyl and 5, Examples of heteroaryl groups include 1,2,3-, 1,2,4-, 1,3,4-triazolyl, 2,3,4-triazolyl, 1,2,4-triazolyl, and 1,3,4-triazolyl. Substituents on heteroaryl groups may, where appropriate, be located on any atom in the ring system, including a heteroatom.The attachment point of the heteroaryl group can be through any atom in the ring system, including (optionally) a heteroatom (such as a nitrogen atom), or through an atom on any fused carbocyclic ring that may be part of the ring system. The heteroaryl group may be in its N or S oxidized form. Particularly preferred heteroaryl groups include pyridyl, pyrrolyl, quinolinyl, furanyl, thienyl, oxadiazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrimidinyl, indolyl, pyrazinyl, indazolyl, pyrimidinyl, thiophenethyl, thiophenyl, pyranyl, carbazolyl, acridinyl, quinolinyl, benzimidazolyl, benzothiazolyl, purinyl, cinnolinyl, and pterdinyl. Particularly preferred heteroaryl groups include monocyclic heteroaryl groups.

[0064] Further embodiments of the invention include those in which the compound of formula (I) is isotopically labeled. However, other specific embodiments of the invention that may be mentioned include those in which the compound of formula (I) is not isotopically labeled.

[0065] The term "isotopically labeled" as used herein includes reference to a compound of formula (I) having a non-natural isotope (or a distribution of non-natural isotopes) at one or more positions in the compound. It will be understood by those skilled in the art that a reference herein to "one or more positions in a compound" means one or more atoms of a compound of formula (I). Thus, the term "isotopically labeled" includes reference to a compound of formula (I) that is isotopically enriched at one or more positions in the compound.

[0066] The compounds of formula (I) can be isotopically labelled or enriched with any of the following isotopes: hydrogen, carbon, nitrogen, oxygen, sulfur, fluorine, chlorine, bromine and / or iodine, either radioactive or non-radioactive isotopes. Particular isotopes that may be mentioned in this respect include: 2 H, 3 H,11 C. 13 C. 14 C. 13 N, 15 N, 15 O. 17 O. 18 O. 35 S, 18 F, 37 Cl, 77 Br, 82 Br, and 125 I can be mentioned.

[0067] When the compounds of formula (I) are labeled or enriched with a radioactive or non-radioactive isotope, compounds of formula (I) that may be mentioned include those that exhibit an isotopic distribution in which at least one atom in the compound is the following radioactive or non-radioactive isotope, and the radioactive or non-radioactive isotope of the atom in question is present at a level at least 10% (e.g. 10% to 5000%, particularly 50% to 1000%, more particularly 100% to 500%) higher than the natural level.

[0068] In an embodiment of the present invention, the compound of formula (I) is Ca 3.1 Those that selectively inhibit calcium-activated potassium channel subtypes.

[0069] K Ca 3.1 As used herein with respect to inhibition of calcium-activated potassium channels, the terms "selective" and "selectivity" refer to the inhibition of Ca of the same compound at the same temperature (e.g., room temperature, such as 298 K). v 1.2 IC determined for binding to calcium-activated potassium channel subtypes 50 IC at least 10 times lower (e.g., at least 20, 50, 100, 500, or 1000 times lower) than the value 50 K value of the compound Ca Contains reference to binding to 3.1.

[0070] An embodiment of the present invention that may be mentioned is that the compound of formula (I) Ca3.1 Selective inhibitors of calcium-activated potassium channels.

[0071] K Ca 3.1 As used herein with respect to the inhibition of calcium-activated potassium channels, the terms "selective" and "selectivity" include the Ca 3.1 References to the binding of compounds to calcium-activated potassium channels are included, and binding of the same compound to different calcium-activated potassium channel subtypes (e.g., Ca v 1.2 IC measured for binding to calcium-activated potassium channel subtypes 50 at least one tenth (e.g., at least 20, 50, 100, 500, or 1000 times smaller) than the value. Ca 3.1 Selectivity for calcium-activated potassium channels can be over one other calcium-activated potassium channel subtype, but in certain embodiments of the invention, is over two or more (e.g., all other) calcium-activated potassium channel subtypes.

[0072] In a second aspect of the present invention, K Ca 3.1 There is provided a compound according to the first aspect or a derivative thereof for use as a channel inhibitor. An embodiment of the invention which may be mentioned is that the compound of formula (I) Ca 3.1 channel selective inhibition.

[0073] As used herein with respect to inhibition of the KCa3.1 channel, the terms "selective" and "selectivity" include the IC20 determined for the binding of the same compound to one or more of the following channels: 50 An IC at least 10-fold lower (e.g., at least 20-, 50-, 100-, 500-, or 1000-fold lower) than the value 50 The compound has a K value Ca 3.1 Includes reference to coupling channels: at the same temperature (e.g., room temperature, e.g., 298 K), K Ca 1.1 channel, KCa 2.2 channel, K Ca 2.3 channel, KV1.1 channel, KV1.2 channel, K V 1.3 channel, K V 1.4 channel, K V 1.5 channel, K V 1.7 channel, K V 3.1 channel, K V 4.2 channel, K V 11.1 channel. Ca Selectivity for the 3.1 channel can be over one other calcium channel subtype and / or voltage-gated channel subtype, but in certain embodiments of the invention is over two or more (e.g., all other) calcium channel subtypes and voltage-gated channel subtypes.

[0074] In embodiments of the invention, one or more of the following may apply: (Ai) R1 may be selected from H, F, Cl, Br, CF3 or NO2; (Aii) R2 and R3 may be independently selected from H, F, Cl, Br, CH3, CF3, or NO2; (Aiii) R4 may be selected from H, F, Cl, Br, or CF3; (Aiv) R5 and R6 are independently R 9a C(O)O-, R 9b OC(O)-, or alkyl ketones having 1 to 10 carbon atoms, the carbon atoms of which are branched or unbranched and unsubstituted or substituted with one or more substituents selected from Cl, F and NO2; (Av) R7 and R8 can be independently selected from H or C1-C3 alkyl, unsubstituted or substituted with one or more substituents selected from F and Cl; or One of the pairs of R5 and R7 or R6 and R8, together with the carbon atom to which they are attached, may form a 4-14 membered ring system that is carbocyclic or heterocyclic and is unsubstituted or substituted with one or more substituents selected from F, Cl, =O, and C1-C6 alkyl; (Avi) R 9a ~R 9f and R 10a ~R 10e may be independently selected from H, and C1-C6 alkyl that is unsubstituted or substituted with one or more substituents selected from F and Cl.

[0075] In certain embodiments of the invention, one or more of the following may apply: R1 is selected from H, F, Cl, or CF3; R2 and R3 are independently selected from H, F, Cl, or CF3; R4 is selected from H, F, Cl, or CF3; R5 and R6 are independently R 9b OC(O)-, or an alkyl ketone having 1 to 3 carbon atoms, the carbon atoms of which are unsubstituted or substituted with one or more substituents selected from Cl and F; R7 and R8 are independently selected from H or methyl that is unsubstituted or substituted with one or more substituents selected from F and Cl.

[0076] In further particular embodiments of the invention, one or more of the following may apply: R1 is selected from H, F, or Cl; R2 is selected from CF3 or, more specifically, H or F; R3 is selected from H or CF3; R4 is H; R5 and R6 are independently selected from CH3OC(O)- or propan-2-onyl (e.g., both R5 and R6 are CH3OC(O)-); R7 and R8 are independently selected from H and CH3.

[0077] In certain embodiments of the invention that may be mentioned herein, at least one of R7 and R8 is H. For example, both R7 and R8 may be H. In another embodiment that may be mentioned herein: R7 may be H and R8 may be CH3; Both R7 and R8 may be CH3; or R7 may be CH3 and R8 may be H.

[0078] The compound of formula (I), or a salt and / or solvate thereof, may be selected from one or more compounds from the following list: [Table 7] [Table 8]

[0079] More specifically, the compound of formula (I), or a salt and / or solvate thereof, may be selected from one or more compounds from the following list: [Table 9] [Table 10]

[0080] Even more specifically, the compound of formula (I), or a salt and / or solvate thereof, may be selected from one or more compounds from the following list: [Table 11]

[0081] Even more specifically, the compound of formula (I), or a salt and / or solvate thereof, may be selected from one or more compounds from the following list: [Table 12]

[0082] For example, a compound of formula (I), or a salt and / or solvate thereof, [ka] It could be.

[0083] As can be understood, the compound of the present invention may be suitable for treating subjects.Therefore, in a further aspect of the present invention, there is provided a pharmaceutical composition comprising the compound of formula (I) above, or its salt and solvate, in combination with one or more pharma-ceutically acceptable carriers, adjuvants or vehicles.

[0084] The compounds of formula (I) may be administered in the form of a pharmaceutical preparation containing the compound in a pharma- ceutically acceptable dosage form by any suitable route, in particular orally, intravenously, intramuscularly, cutaneously, subcutaneously, mucosally (e.g., sublingually or buccally), rectally, transdermally, nasally, pulmonary (e.g., trachea or bronchus), topically or by other parenteral routes. Particular modes of administration include oral, intravenous, cutaneous, subcutaneous, nasal, intramuscular or intraperitoneal administration.

[0085] The compounds of formula (I) are generally administered as pharmaceutical preparations mixed with pharma- ceutically acceptable adjuvants, diluents or carriers, which may be selected in consideration of the intended route of administration and standard pharmaceutical practice. Such pharma-ceutically acceptable carriers may be chemically inert to the active compounds and may have no adverse side effects or toxicity under the conditions of use. Suitable pharmaceutical preparations may be found, for example, in Remington The Science and Practice of Pharmacy, 19th ed., Mack Printing Company, Easton, Pennsylvania (1995). For parenteral administration, parenterally acceptable aqueous solutions may be used that are pyrogen-free and have the required pH, isotonicity and stability. Suitable solutions are well known to those skilled in the art, and many methods are described in the literature. A brief review of drug delivery methods is also found, for example, in Langer, Science (1990) 249, 1527.

[0086] If not, the preparation of suitable formulations can be routinely accomplished by those skilled in the art using routine techniques and / or in accordance with standard and / or accepted pharmaceutical practices.

[0087] The amount of the compound of formula (I) in any pharmaceutical formulation used in accordance with the present invention will depend on a variety of factors, such as the severity of the condition being treated, the particular patient being treated, and the compound being employed. In any event, the amount of the compound of formula (I) in the formulation can be routinely determined by one of ordinary skill in the art.

[0088] For example, solid oral compositions such as tablets and capsules may contain 1-99% (w / w) active ingredient; 0-99% (w / w) diluent or filler; 0-20% (w / w) disintegrant; 0-5% (w / w) lubricant; 0-5% (w / w) flow aid; 0-50% (w / w) granulating or binding agent; 0-5% (w / w) antioxidant; and 0-5% (w / w) pigment. Controlled release tablets may further contain 0-90% (w / w) release controlling polymer.

[0089] Parenteral formulations (such as solutions or suspensions for injection, or solutions for infusion) may contain 1-50% (w / w) active ingredient; and 50% (w / w) to 99% (w / w) of a liquid or semisolid carrier or vehicle (e.g., a solvent such as water); and 0-20% (w / w) of one or more other excipients, such as buffers, antioxidants, suspension stabilizers, tonicity adjusting agents and preservatives.

[0090] Depending on the disease to be treated, the patient, and the route of administration, the compounds of formula (I) may be administered in various therapeutically effective doses to patients in need thereof.

[0091] However, in the context of the present invention, the dose administered to a mammal, particularly a human, must be sufficient to produce a therapeutic response in the mammal over a reasonable period of time.Those skilled in the art will recognize that the selection of the exact dose and composition, as well as the most appropriate delivery regimen, will also be influenced by, among other things, the pharmacological properties of the formulation, the nature and severity of the condition being treated, and the physical condition, mental acuity of the recipient, as well as the potency of the particular compound, the age, condition, weight, sex and response of the patient being treated, and the stage / severity of the disease.

[0092] Administration may be continuous or intermittent (e.g., by bolus injection). The dosage is also determined by the timing and frequency of administration. For oral or parenteral administration, the dosage may range from about 0.01 mg to about 1000 mg of the compound of formula (I) per day.

[0093] In any event, a physician or other skilled artisan can routinely determine the actual dosage that is most suitable for an individual patient. The dosages above are examples of the average case. Of course, there may be individual cases where higher or lower dosage ranges are merited, and these are within the scope of the present invention.

[0094] As will be appreciated, a further aspect of the present invention relates to a compound of formula (I) above, or a salt and / or solvate thereof, for use in medicine.

[0095] Thus, further aspects of the present invention relate to: (a)K Ca 3. A compound of formula (I) as defined above, or a salt or solvate thereof, for use in the treatment or prevention of a disease condition associated with an increase or altered activity of 1. (b)K Ca 3. The use of a compound of formula (I) as defined above, or a salt or solvate thereof, for the manufacture of a medicament for the treatment or prevention of a disease condition associated with an increase or altered activity of 1. (c)K Ca 3. A method for treating a disorder or condition associated with an increase or altered activity of 1, comprising administering to a subject in need thereof an effective amount of a compound of formula (I) as defined above, or a salt or solvate thereof.

[0096] In various embodiments of the present invention, K Ca 3.1 Disease conditions associated with increased or altered activity may be selected from one or more of leukemia, particularly inflammatory bowel disease (IBD), fibrotic diseases (lung, liver, kidney, heart, conjunctiva, cornea), nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), glioma (glioblastoma), lung cancer, pancreatic cancer, hepatocellular carcinoma, ovarian cancer, colorectal cancer, cystic fibrosis, diabetic kidney disease, glomerulonephritis, bone resorption, inflammatory arthritis, multiple sclerosis, atherosclerosis, restenosis after angioplasty, in-stent neoatherosclerosis, stroke, traumatic brain injury, Alzheimer's disease, hereditary stomatitis, sickle cell anemia, asthma, allergic rhinitis, microglial activation, nitric oxide-dependent neurodegeneration, neuro-oncological diseases, and rare red blood cell disorders. For example, K Ca3.1 The disease state associated with increased or altered activity may be selected from one or more of leukemia, particularly inflammatory bowel disease (IBD), fibrotic disease (lung, liver, kidney, heart, conjunctiva, cornea), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), glioma (glioblastoma), lung cancer, pancreatic cancer, hepatocellular carcinoma, ovarian cancer, colorectal cancer, cystic fibrosis, diabetic kidney disease, glomerulonephritis, bone resorption, inflammatory arthritis, multiple sclerosis, atherosclerosis, restenosis after angioplasty, in-stent neoatherosclerosis, stroke, traumatic brain injury, Alzheimer's disease, hereditary stomatitis, sickle cell anemia, asthma, allergic rhinitis, microglial activation and nitric oxide dependent neurodegeneration.

[0097] In certain embodiments that may be mentioned herein, K Ca 3.1 The disease state associated with increased or altered activity may be stroke.

[0098] As will be appreciated, the compounds or derivatives of formula (I) disclosed herein have potency, K Ca 3.1 channel selectivity, oral bioavailability, excellent brain penetration, and good tolerability in repeated dose toxicity studies in rodents. Furthermore, the compounds or derivatives of formula (I) disclosed herein have the advantage of being K Ca 3.1 activity has been found to be effective in the treatment of stroke, a disease state associated with increased or altered activity.

[0099] The aspects of the invention described herein (e.g., the compounds, combinations, methods and uses described above) may have advantages to the physician and / or patient in treating the conditions described herein, such as being more convenient, more effective, less toxic, having greater selectivity, having a broader spectrum of activity, being more potent, causing fewer side effects, or having other useful pharmacological properties, as compared to similar compounds, combinations, methods (treatments) or uses known in the prior art for use in treating those conditions or otherwise.

[0100] Compounds of formula (I) can be synthesized using known techniques, as shown in the following examples. Other compounds can be prepared in a similar manner. The compounds of the invention can be isolated from their reaction mixtures using conventional techniques (e.g., recrystallization, column chromatography, preparative HPLC, etc.).

[0101] Working Example material Ammonium carbonate ((NH4)2CO3), acetic acid, ammonium acetate (NH4OAc), dicyclohexylcarbamide, 4-dimethylaminopyridine, n,o-dimethylhydroxylamine HCl, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), ethyl chloroformate, methyl acetoacetate, piperidine and sodium metaperiodate were purchased from Avra ​​Synthesis Pvt Ltd. Sodium chloride, potassium chloride, magnesium chloride, calcium chloride, ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), D-glucose, guanosine 5'-triphosphate sodium salt hydrate (Na2-GTP), adenosine 5'-triphosphate magnesium salt (Mg-ATP), ketoconazole, quinidine, sulfaphenazolefor, nootkatone, verapamil, warfarin, naltrexone, loperamide hydrochloride, phenacetin, reserpine, β-nicotinamide adenine dinucleotide 2'-phosphate reduced tetrasodium salt hydrate (NADPH), N-methyl-2-pyrrolidone (NMP), Solutol HS-15, polyethylene glycol 400 (PEG-400), tocopherolane (TPGS), manganese oxide, and dichloromethane were purchased from Sigma-Aldrich. Osmium(VIII) oxide was purchased from Chempure Pte Ltd. Methyl propionate, 4-chloro-3-(trifluoromethyl)benzaldehyde, 3,4-difluoro-5-(trifluoromethyl)benzoic acid, 3-fluoro-5-(trifluoromethyl)benzaldehyde, potassium vinyltrifluoroborate (95%), 5-bromo-2-fluoro-3-(trifluoromethyl)benzoic acid and 4-fluoro-3-(trifluoromethyl)benzaldehyde were purchased from Combi-Blocks Inc. 1,1'-bis-(diphenylphosphino)-ferrocene]-palladium dichloride was purchased from Hindustan Platinum Pte Ltd. Chloroform was purchased from SAI Enterprises.Isopropylmagnesium chloride-lithium chloride complex, 1.3 M solution in THF, 1 mol of hydrogen chloride in 1,4-dioxane, and 3 M solution of methylmagnesium bromide in diethyl ether were purchased from Sainor Laboratories Pte. Ltd. N,N,N,N-Tetramethylguanidinium azide was purchased from SelectLab Chemicals GmbH. Methyl propionate, tetraethylammonium chloride (TEA-Cl), and 3-(trifluoromethyl)benzaldehyde (97%) were purchased from TCI Chemicals (India) Pte. Ltd. N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES) was purchased from Thermo Fisher Scientific. Furaphylline was purchased from BD Gentest. Formic acid was purchased from Honeywell Research Chemicals. Acetonitrile (ACN) was purchased from Avantor. Tolbutamide was purchased from Supelco. 2,3,5-Triphenyltetrazolium chloride (TCC) was purchased from Vicmed Biotechnology. Edaravone was purchased from TargetMol. All other chemicals and solvents were purchased from industrial chemical suppliers and used directly without further purification.

[0102] Analysis method 1 H NMR spectroscopy All 1 H NMR spectra were recorded on 400 MHz (Bruker) and 500 MHz (Agilent) NMR spectrometers. All chemical shifts are given as δ values ​​relative to tetramethylsilane (TMS) as the internal standard.

[0103] Liquid chromatography-mass spectrometry (LC-MS) For toxicity studies, an LC-MS / MS AB SCIEX API-4000 Triple Quadrapole instrument coupled with a Waters UPLC system was used. For cytochrome P450 enzyme inhibition assays and plasma protein binding assays, a mass spectrometer API-4000 (Applied Biosystems) coupled with an LC SIL-HTc (Shimadzu) was used. For microsomal stability studies, a mass spectrometer TSQ Quantum Ultra (Thermo Scientific) coupled with an LC SIL-HTc (Shimadzu) was used. For compound synthesis analysis, an LCMS(SQD)-2010EV (Shimadzu), an LCMS(SQD)-1200 series LC / G6125B-MS (Agilent), and a UPLC / MS(SQD) (Waters) were used.

[0104] High-Performance Liquid Chromatography (HPLC) Water solubility was measured using a Waters Alliance 2690 HPLC, and compound synthesis analysis was performed using an HPLC 2010CHT (Shimadzu). EXAMPLES

[0105] The dihydropyridines studied in this work are classified into four groups and are shown in Table 1. Group 4 is further divided into three subgroups (4a, 4b, 4c) based on the R7 and R8 moieties.

[0106] [ka] [Table 13]

[0107] The synthesis of group 4b and 4c analogues is shown below. All of these compounds are new chemical entities based on a search of the SciFinder database.

[0108] Dimethyl 4-(4-fluoro-3-(trifluoromethyl)phenyl)-1,4-dihydropyridine-3,5-dicarboxylate (103) [ka] To a stirred solution of 4-fluoro-3-(trifluoromethyl)benzaldehyde (1.80 g, 416.42 mmol, 1.0 equiv.) in acetic acid (800 mL) cooled to 0° C., methyl propionate (2.70 g, 832.84 mMol, 2.0 equiv.) and (NH4)2CO3 (40 g, 416.42 mmol, 1.0 equiv.) were added and the reaction mixture was stirred at 70° C. for 16 h. After completion of the reaction (monitored by thin layer chromatography (TLC)), the reaction mixture was diluted with cold water (1 L) and then extracted with ethyl acetate (EtOAc, 2×1 L). The organic phase was washed with saturated NaHCO3 solution (2 L) and brine solution (2 L), dried over anhydrous Na2SO4, filtered and concentrated to give the crude product. The crude product was triturated with hexanes (800 mL), decanted, then crystallized with MeOH (50 mL) and filtered to give 103 (44 g, 29.4%) as a pale yellow solid. TLC: 50% EtOAc / heptane (Rf: 0.3).

[0109] 1 H NMR (DMSO-d6, 400 MHz): δ 9.32 (br s, 1H), 7.55 - 7.50 (m, 1H), 7.48 - 7.44 (m, 1H), 7.43 - 7.37 (m, 3H), 4.80 (s, 1H), 3.55 (s, 6H).

[0110] LC-MS: 99.59%, m / z = 358.0 [MH]- (Column: EVO-C18 (3.0 x 50 mM, 2.6 μm); Rt: 2.83 min; A: 2.5 mM NHOAc in water, B: acetonitrile (CAN) T / B%: 0.01 / 5, 3 / 90, 5 / 90, 5.5 / 5, 6 / 5; Temperature: 50 °C; and Flow rate: 0.8 mL / min).

[0111] HPLC: 99.94% (Column: X-SELECT CSH C-18 (4.6 x 150 mM, 3.5 μm); Rt: 10.20 min; A: 5.0 mM NH4OAc in water, B: ACN T / B%: 0.01 / 20, 12 / 90, 16 / 90; and Flow rate: 1.0 mL / min).

[0112] Dimethyl 4-(4-fluoro-3-(trifluoromethyl)phenyl)-2-methyl-1,4-dihydropyridine-3,5-dicarboxylate (104) [ka] Methyl 3-azidoacrylate (3b) To a stirred solution of methyl propionate (3a, 2.0 g, 23.80 mMol, 1.0 equiv.) in chloroform (40 mL), N,N,N,N-tetramethylguanidinium azide (4.0 g, 26.19 mMol, 1.1 equiv.) was added and the reaction was stirred at room temperature (RT) for 16 h. After the reaction was complete (monitored by TLC), the reaction mixture was concentrated at 300 mbar in a 35 °C water bath. The crude product was first distilled using house vacuum in a 35 °C water bath to remove most of the residual chloroform. A vacuum pump was attached and the crude product was distilled to give 3b as an off-white solid (1.5 g, crude). The crude product was used directly in the next reaction without further purification. TLC: 20% EtOAc / heptane (Rf: 0.5).

[0113] (E)-Methyl 3-((triphenyl-15-phosphanylidene)amino)acrylate (3c) To a stirred solution of methyl 3-azidoacrylate (1.5 g, 11.81 mMol, 1.0 equiv) in DCM (50 mL) was added triphenylphosphine (3.0 g, 11.80 mMol, 1.0 equiv) and the reaction mixture was stirred at room temperature for 16 h. After the reaction was complete (monitored by TLC), the reaction mixture was directly evaporated under vacuum to give 3c as an off-white solid (1.0 g, crude). TLC: 20% EtOAc / heptane (Rf: 0.5).

[0114] (Z)-2-(4-fluoro-3-(trifluoromethyl)benzylidene)-3-oxobutanoate methyl (2) To a solution of 4-fluoro-3-(trifluoromethyl)benzaldehyde (1, 0.5 g, 2.60 mMol, 1.0 equiv.) in toluene (10 mL), piperidine (22.1 mg, 0.26 mMol, 0.1 equiv.) and acetic acid (15.6 mg, 0.26 mMol, 0.1 equiv.) were added at 0 °C and the reaction mixture was stirred at RT for 16 h. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with cold water (20 mL) and extracted with DCM (2 × 50 mL). The organic phase was washed with brine solution (20 mL), dried over anhydrous Na2SO4, filtered and concentrated to give the crude product, which was purified by Combiflash chromatography using 20-30% EtOAc in hexane as the eluent to give 2 as a pale yellow solid (0.5 g, 66.2%). TLC: 30% EtOAc / heptane (Rf: 0.2).

[0115] 104 To a stirred solution of 2 (0.5 g, 1.72 mMol, 1.0 equiv) in chloroform (20 mL) was added 3c (0.930 g, 2.58 mMol, 1.5 equiv) and the reaction mixture was stirred at 40° C. for 6 h. The reaction progress was monitored by TLC and the product was worked up and purified following the protocol for 2 above to give 104 as a pale yellow solid (0.2 g, 31%). TLC: 40% EtOAc / heptane (Rf: 0.2).

[0116] 1 H NMR (DMSO-d6, 400 MHz): δ 9.36 (br s, 1H), 7.55 - 7.50 (m, 1H), 7.48 - 7.44 (m, 2H), 7.43 - 7.37 (m, 1H), 4.82 (s, 1H), 3.55 (s, 6H) 2.25 (s, 3H).

[0117] LC-MS: 99.91%, m / z = 374.1 [M+H]+ (Column: EVO-C18 (3.0 x 50 mM, 2.6 μm); Rt: 2.8\8 min; A: 2.5 mM ammonium formate in water, B: ACN T / B%: 0.01 / 5, 3 / 90, 5 / 90, 5.5 / 5, 6 / 5; Temperature: 50 °C; and Flow rate: 0.8 mL / min).

[0118] HPLC: 99.94% (Column: X-SELECT CSH C-18 (4.6 x 150 mM, 3.5 μm); Rt: 10.95 min; A: 5.0 mM ammonium acetate (NH4OAc) in water, B: ACN T / B%: 0.01 / 20, 12 / 90, 16 / 90; and Flow rate: 1.0 mL / min).

[0119] Dimethyl 4-(3-(trifluoromethyl)phenyl)-1,4-dihydropyridine-3,5-dicarboxylate (108) [ka] To a stirred solution of 3-(trifluoromethyl)benzaldehyde (1, 20 g, 114.92 mMol, 1.0 equiv) in acetic acid (200 mL) cooled to 0° C., methyl propionate (2, 20.45 mL, 229.85 mMol, 2.0 equiv) and (NH4)2CO3 (11 g, 114.92 mmol, 1.0 equiv) were added and stirred for 16 h at 80° C. After the reaction was complete (monitored by TLC), the reaction mixture was diluted with cold water (400 mL) and then extracted with EtOAc (2×500 mL). The organic layer was washed with saturated NaHCO3 solution (500 mL) and brine solution (500 mL), dried over anhydrous Na2SO4, filtered and concentrated to give the crude product, which was purified by Combi-Flash chromatography using 30-40% EtOAc in hexane as eluent to give 108 as a pale yellow solid (11.0 g, 28%). TLC: 40% EtOAc / heptane (Rf: 0.2).

[0120] 1 H NMR (DMSO-d6, 400 MHz): δ 9.32 (br s, 1H), 7.55 - 7.50 (m, 3H), 7.48 - 7.44 (m, 1H), 7.43 - 7.37 (m, 2H), 4.80 (s, 1H), 3.55 (s, 6H).

[0121] LC-MS: 99.54%, m / z = 340.0 [MH]- (Column: EVO-C18 (3.0 x 50 mM, 2.6 μm); Rt: 2.65 min; A: 2.5 mM NHOAc in water, B: ACN T / B%: 0.01 / 5, 3 / 90, 5 / 90, 5.5 / 5, 6 / 5; Temperature: 50 °C; and Flow rate: 0.8 mL / min).

[0122] HPLC: 99.91% (Column: X-SELECT CSH C-18 (4.6 x 150 mM, 3.5 μm); Rt: 9.43 min; A: 5.0 mM NH4OAc in water, B: ACN T / B%: 0.01 / 20, 12 / 90, 16 / 90; and Flow rate: 1.0 mL / min).

[0123] 4-(3-Fluoro-5-(trifluoromethyl)phenyl)-1,4-dihydropyridine-3,5-dicarboxylate (109) [ka] A solution of 3-fluoro-5-(trifluoromethyl)benzaldehyde (1, 0.100 g, 0.5208 mMol, 1.0 equiv) and methyl propionate (2, 0.085 g, 1.041 mMol, 2.0 equiv) in acetic acid (10 mL) was stirred, (NH4)2CO3 (0.049 g, 0.5208, 1.0 equiv) was added slowly at room temperature, and the reaction mixture was heated at 70 °C for 14 h. After complete consumption of the starting material (monitored by TLC), the reaction mixture was cooled to room temperature and slowly quenched with ice-cold water (10 mL). The aqueous layer was extracted with DCM (15 mL × 2). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, and concentrated under reduced pressure to give the crude product, which was purified by combiflash column chromatography using 10–40% EtOAc in n-hexane to give 109 as a pale yellow solid. (0.040 g, 22%). TLC: 40% EtOAc / Hexanes (Rf: 0.5).

[0124] 1H NMR (400 MHz, DMSO-d6) δ 9.36 (brs, 1H), 7.40 - 7.50 (m, 3H), 7.32 (s, 1H), 7.26 (d, J = 7.9 Hz, 1H), 4.81 (s, 1H), 3.53 (s, 6H).

[0125] LC-MS: 99.32%, m / z = 360.0 [M+H]+ (Column: X-Select CSH C18 (3.0 x 50 mM, 2.5 μm); Rt: 1.941 min; A: 0.05% formic acid in water:ACN (95:05), B: 0.05% formic acid in ACN. Temperature: 50 °C; and flow rate: 1.2 mL / min).

[0126] HPLC: 99.45% (Column: X-SELECT CSH C-18 (4.6 x 150 mm, 3.5 μm); Rt: 8.48 min; A - 0.1% formic acid in water, B: ACN T / B%: 0.01 / 5, 1.0 / 5, 8.0 / 100, 12.0 / 100, 14.0 / 5, 18.0 / 5 and flow rate: 1.0 mL / min).

[0127] Dimethyl 4-(3,4-difluoro-5-(trifluoromethyl)phenyl)-1,4-dihydropyridine-3,5-dicarboxylate (110) [ka] (3,4-difluoro-5-(trifluoromethyl)phenyl)methanol (2) To a stirred solution of 3,4-difluoro-5-(trifluoromethyl)benzoic acid (1, 0.500 g, 2.212 mMol) in THF (20 mL) was added BH3:THF (6.6 mL, 6.637 mMol) slowly at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred for 12 h. After complete consumption of the starting material (monitored by TLC), the reaction mixture was quenched with 3M HCl (30 mL) and the aqueous layer was extracted with EtOAc (20 mL). The organic layer was washed with brine (10 mL), dried over Na2SO4, and concentrated under reduced pressure to give 2 as a viscous colorless oil (0.300 g, 64%). The resulting crude product was used directly in the next reaction without further purification. TLC: 5% MeOH in DCM (Rf: 0.6).

[0128] 1H NMR (400 MHz, DMSO-d6) δ 7.45 - 7.55 (m, 1H), 7.25 (s, 1H), 6.95 (s, 1H), 4.58 - 4.68 (s, 2H).

[0129] 3,4-Difluoro-5-(trifluoromethyl)benzaldehyde (3) To a stirred solution of (3,4-difluoro-5-(trifluoromethyl)phenyl)methanol (2, 0.300 g, 1.415 mMol) in DCM (20 mL), MnO2 (0.738 g, 8.490 mMol) was slowly added at room temperature and stirred for 12 h. After complete consumption of the starting material (monitored by TLC), the reaction mixture was filtered through a pad of Celite. The Celite pad was washed with DCM (5 mL) and the resulting filtrate was concentrated under reduced pressure to give 3 as a viscous colorless oil (0.200 g, 67%). The resulting crude product was used directly in the next reaction without further purification. TLC: 40% EtOAc / Hexane (Rf: 0.8).

[0130] 1 H NMR (400 MHz, DMSO-d6) δ 9.88 (br. s, 1H), 7.73 (s, 1H), 7.45 (s, 1H).

[0131] 110 A solution of 3,4-difluoro-5-(trifluoromethyl)benzaldehyde (3, 0.200 g, 0.9523 mMol) and methyl propionate (2, 0.159 g, 1.904 mMol) in acetic acid (10 mL) was stirred, (NH4)2CO3 (0.091 g, 0.9523 mMol) was added slowly at room temperature, and the reaction mixture was heated at 75 °C for 16 h. After complete consumption of the starting material (monitored by TLC), the reaction mixture was cooled to room temperature and quenched slowly with ice-cold water (10 mL). The aqueous layer was extracted with DCM (20 mL x 2). The combined organic layers were washed with brine (10 mL) and Na2S O4The mixture was dried at 40° C. and concentrated under reduced pressure to give the crude product. The crude product was purified by combi-flash column chromatography using 0-40% EtOAc in n-hexane to give 110 as a pale yellow solid (0.040 g, 11%). TLC: 40% EtOAc / Hexane (Rf: 0.5).

[0132] 1 H NMR (400 MHz, DMSO-d6) δ 9.38 (br. s, 1H), 7.40 - 7.50 (m, 3H), 7.30 (s, 1H), 4.81 (s, 1H), 3.55 (s, 6H).

[0133] LC-MS: 99.64%, m / z = 360.0 [M+H]+ (Column: X-Select CSH C18 (3.0 x 50 mm, 2.5 μm); Rt: 2.034 min; A: 0.05% formic acid in water:ACN (95:5), B: 0.05% formic acid in ACN; Temperature: 50 °C; and Flow rate: 1.2 mL / min).

[0134] HPLC: 98.11% (column; X-SELECT CSH C-18 (4.6 x 150 mm, 3.5 μm); Rt: 9.043 min; A - 0.1% formic acid in water, B: ACN T / B%: 0.01 / 5, 1.0 / 5, 8.0 / 100, 12.0 / 100, 14.0 / 5, 18.0 / 5; and flow rate: 1.0 mL / min).

[0135] Dimethyl 4-(4-chloro-3-(trifluoromethyl)phenyl)-1,4-dihydropyridine-3,5-dicarboxylate (113) [ka] To a solution of 4-chloro-3-(trifluoromethyl)benzaldehyde (1, 0.100 g, 0.4807 mMol) and methyl propionate (2, 0.080 g, 0.9615 mMol) in acetic acid (10 mL), (NH4)2CO3 (0.046 g, 0.4807) was added slowly at room temperature and the reaction mixture was heated at 70 °C for 14 h. After complete consumption of the starting material (monitored by TLC), the reaction mixture was cooled to room temperature and slowly quenched with ice-cold water (10 mL). The aqueous layer was extracted with DCM (20 mL × 2). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, and concentrated under reduced pressure to give the crude product. The crude product was purified by combiflash column chromatography using 0–40% EtOAc in n-hexane to give 113 as a pale yellow solid (0.040 g, 22%). TLC: 40% EtOAc / Hexane (Rf: 0.8).

[0136] 1 H NMR (400 MHz, DMSO-d6) δ 9.33(br. s, 1H), 7.63(d, J = 8.01 Hz, 1H), 7.57(s, 1H), 7.40 - 7.50(m, 3H), 4.79(s, 1H), 3.35(s, 6H).

[0137] LC-MS: 99.75%, m / z = 376.0 (M+H)+ (Column: X-Select CSH C18 (3.0 x 50 mm, 2.5 μm); Rt: 1.986 min; A: 0.05% formic acid in water:ACN (95:05), B: 0.05% formic acid in ACN; Temperature: 50 °C; and Flow rate: 1.2 mL / min).

[0138] HPLC: 99.42% (Column: X-SELECT CSH C-18 (4.6 x 150 mm, 3.5 μm); Rt: 8.715 min, A - 0.1% formic acid in water, B: ACN T / B%: 0.01 / 5, 1.0 / 5, 8.0 / 100, 12.0 / 100, 14.0 / 5, 18.0 / 5; and Flow rate: 1.0 mL / min). EXAMPLES

[0139] K Ca A panel of dihydropyridines on 3.1 channels was screened using patch clamp to understand structure-activity relationships.

[0140] K Ca 3.1 Patch clamp protocol K Ca 3.1 The effects of compounds on channels were assessed by patch clamp using the QPatch HTX automated electrophysiology platform (Sophion, Denmark) and by manual patch clamp (HEKA, Germany). For QPatch experiments, the gigaseal and whole-cell requirements for automated electrophysiology were: minimum seal resistance = 0.1 GΩ; holding potential = -80 mV; holding pressure = -20 mbar; and positioning pressure = -70 mbar. K Ca 3.1 For the experiment, the external solution was Na + - Ringer's solution, which contained (in mM): 160 NaCl; 10 HEPES; 4.5 KCl; 1 mgCl2; and 2 CaCl2 (pH = 7.4, 310 mOsm). The internal solution contained (in mM): 120 KCl; 10 HEPES; 1.75 mgCl2; 1 Na2ATP; 10 EGTA; and 8.6 CaCl2 (1 μM free Ca 2+ ) (pH = 7.2, 300 mOsm). After establishment of the whole-cell configuration, cells were held at -80 mV, held at -80 mV for 20 ms, stepped to -120 mV for 20 ms, ramped from -120 to +40 mV for 200 ms, then back to -120 mV for 20 ms. This pulse protocol was applied every 10 seconds. The slope of the current (amperes / sec) was measured using Sophion QPatch software and exported to Microsoft Excel and GraphPad Prism 7 for analysis. The decrease in slope between -85 and -65 mV was used to determine the K Ca 3.1 IC of inhibition 50 was determined. Curve fitting and IC 50The determination was performed using GraphPad Prism software.

[0141] Results and Discussion Dihydropyridines IC 50 are summarized in Table 2. The first group consisted of those with IC > 5 μM 50 Value K Ca The second group blocked the channel with K 3.1. The second group blocked the channel with K 1–5 μM. The third group blocked the channel with K 100–200 nM. Ca The fourth group blocked K Ca 3.1 was blocked. K of selected compounds of groups 2, 3, 4a, 4b, and 4c Ca 3.1 The effect on current is shown in Figure 3.

[0142] [Table 14] EXAMPLES

[0143] Dihydropyridines inhibit L-type voltage-gated calcium channels, so select analogs were used to V Tested against 1.2.

[0144] Ca V 1.2 Patch clamp protocol Ca V 1.2 The effect of compounds on channels was assessed by manual patch clamp using an EPC-10 HEKA amplifier. The external solution contained (mM) 140 TEA-Cl, 2 mg Cl2, 10 CaCl2, 10 HEPES, and 5 D-glucose (pH = 7.4). The internal solution contained (mM) 120 CsCl, 1 mg Cl2, 10 HEPES, 10 EGTA, 0.3 Na2-GTP, and 4 mg-ATP (pH = 7.2). After establishment of the whole-cell configuration, the membrane potential was held at -80 mV to measure Ca VThe 1.2 current was recorded and then depolarized to +10 mV for 0.3 s (the test pulse was slightly modified for lead IV testing). This protocol was repeated at 20 s intervals to measure Ca V 1.2 The effect of test compounds on peak current was observed. Each cell was incubated with each test compound for 5 min or until the current reached a steady state. Compounds were applied at multiple concentrations, ranging from low to high. Each cell served as its own control. The reduction in peak current was indicative of Ca V 1.2 IC of inhibition 50 was used to determine the curve fit and IC 50 Calculations were performed using IGOR software.

[0145] Results and Discussion Table 3 shows the selected analogs and K Ca 3.1 and Ca V The selectivity of selected analogs against 1.2 is compared. Analogs of group 2 have K Ca Ca than 3.1 V Analogs in group 3 showed selectivity for Ca 1.2. V K than 1.2 Ca Analogs from group 4 showed ~10-fold selectivity for Ca V K than 1.2 Ca 3.1, and analogs of group 4c showed >50-fold selectivity against K Ca 3.1 was the most selective. Ca Low IC of 3.1 nM 50 Block and Ca V K than 1.2 Ca The pharmacophore required for >1000-fold selectivity over 3.1 is shown in FIG.

[0146] [Table 15] EXAMPLES

[0147] Selected analogs from group 4 were tested on relevant potassium channels.

[0148] Potassium Channel Patch Clamp Protocol The effects of group 4 compounds on relevant potassium channels were assessed by patch clamp using a QPatch HTX automated electrophysiology platform (Sophion, Denmark). Giga-seal and whole-cell requirements for automated electrophysiology were as follows: minimum seal resistance = 0.1 GΩ, holding potential = -80 mV, holding pressure = -20 mbar, and positioning pressure = -70 mbar. Buffer compositions and voltage protocols for each specific ion channel tested are shown in Table 4.

[0149] [Table 16]

[0150] Results and Discussion Analogs of groups 4a, 4b, and 4c have higher K than related potassium channels. Ca It showed >1000-fold selectivity over 3.1 (Table 5). [Table 17] EXAMPLES

[0151] Compounds 101 and 103 from group 4 were tested for their ability to inhibit cytochrome P450 enzymes. In addition, their plasma protein binding and microsomal stability were evaluated.

[0152] Cytochrome P450 Enzyme Inhibition Assays Microsome suspensions in potassium phosphate buffer (50 mM, pH = 7.4) were mixed with the respective probe substrates and then equilibrated at 37 °C for 5 min. DMSO control, reference inhibitors (ketoconazole for 3A4, quinidine for 2D6, sulfaphenazole for 2C9, nootkatone for 2C19, furafylline for 1A2) and various concentrations (0.009 μM, 0.027 μM, 0.082 μM, 0.247 μM, 0.741 μM, 2.222 μM, 6.667 μM and 20 μM) of compounds 101 or 103 were spiked into the prepared microsome-probe substrate mixture and incubated at 37 °C for 5 min in a shaking water bath. NADPH (10 mM) was added to all samples to initiate the reaction. ACN containing verapamil (200 ng) and warfarin (200 ng) as internal standards was added to the mixture and incubated at 37°C for 10 min before stopping the reaction. Samples were gently vortexed and centrifuged at 1021 g for 20 min at 4°C before being injected into the LC-MS / MS system. The formation of metabolites for each substrate under the above conditions was estimated using the following formula: Percent inhibition = [1-(Test area ratio / Control area ratio)]x100. IC 50 Values ​​were determined using a sigmoidal dose-response curve (variable slope) in GraphPad Prism® 5 software.

[0153] Plasma protein binding assays Human and mouse plasma (150 μL) containing test compound (3 μM, final concentration) and sodium phosphate buffer (150 μL, 100 mM, pH 7.4) was added to the equilibration dialysis device and equilibrated at 37° C. for 4.5 hours with constant shaking. After equilibration, 10 μL of plasma was removed from the first half of the well and mixed with 50 μL of blank buffer, then quenched with 200 μL of 0.05% formic acid ACN solution containing 100 ng / mL loperamide, phenacetin and tolbutamide as internal standards. Similarly, 50 μL of plasma was taken from the second half of the well and mixed with 10 μL of blank plasma, then quenched. To prepare the recovery samples, 10 μL of plasma containing 3 μM of compound 101 or 103 was added to 50 μL of blank buffer and quenched. All samples were centrifuged at 14,000 rpm for 5 min at 4°C. Warfarin and naltrexone were used as positive controls. Supernatants from all samples were analyzed by LC-MS / MS.

[0154] Microsomal stability studies Human microsomes (20 mg / mL) were suspended in potassium phosphate buffer (66.7 mM, pH = 7.4) as the incubation mixture. 1 μL of test compound or control (1.1 mM) was added to the incubation mixture to give a working concentration of 1.1 μM and aliquoted into four tubes for a four-time point assay (0, 5, 15, and 30 min). All tubes and NADPH solution (10 mM) were preincubated for 5 min at 37 °C in a shaking water bath. After preincubation, NADPH solution (10 mM) was added to the 5 min, 15 min, and 30 min tubes. Buffer was added to the 0 min tube to give a final concentration of 1 μM of test compound or reference standard. At the end of the incubation period in each tube, the reaction was stopped by adding quenching solution (ACN with 100 ng / mL warfarin and loperamide as internal standards). The resulting samples were centrifuged at 3,220 g for 20 min, and the supernatant from each reaction tube was collected for LC-MS / MS analysis.

[0155] Results and Discussion Group 4c analogs have a higher K activity than cytochrome P450 enzymes compared to group 4a compounds. Ca It was more selective for 3.1, had less plasma protein binding, lower cLogP values, and better stability and solubility (Table 6). [Table 18] Compound 103 in group 4c exhibited low nanomolar potency (IC50 = 6 nM) and K Ca 3.1, compared to other channels and a panel of ~100 molecular targets, K Ca Because it has >1000-fold selectivity against 3.1, it was used in subsequent studies. EXAMPLES

[0156] The selectivity of compound 103 was evaluated by competitive binding, enzymatic, and uptake assays against 97 targets.

[0157] Competitive binding assay The experimental conditions for each competitive binding assay are shown in Table 7. Compound 103 was tested at 3 μM. Results are expressed as percent inhibition of control specific binding [100-(measured specific binding / control specific binding×100)]. IC 50 Values ​​and Hill coefficients (nH) were determined by non-linear regression analysis of competition curves generated with mean replicate values ​​using Hill equation curve fitting implemented in Cerep developed software (Hill software) and were verified by comparison with data generated by the commercial software SigmaPlot® 4.0.

[0158] [Table 19] [Table 20] [Table 21] [Table 22] [Table 23]

[0159] Enzyme and uptake assays The experimental conditions for the individual enzymes and uptake assays are shown in the table. Compound 103 was tested at 3 μM. Results are expressed as percent inhibition of control specific activity [100-(measured specific activity / control specific activity×100)]. IC 50 Value, E.C. 50 Values, and Hill coefficients (nH), were determined by nonlinear regression analysis of concentration-response curves generated with mean replicate values ​​using Hill equation curve fitting implemented in Cerep developed software (Hill software) and verified by comparison with data generated by commercial software SigmaPlot® 4.0.

[0160] [Table 24] [Table 25] Results and Discussion The results are shown in Figure 5. EXAMPLES

[0161] The solubility and pharmacokinetics of compound 103 were evaluated.

[0162] Solubility Test Calibration standards of 1, 5, 10, 50, 100, 200, and 300 μM were prepared in DMSO from 20 mM stocks. A 198 μL aliquot of 0.01 M PBS (pH = 7.4) was dispensed into two wells of a MultiScreen solubility filter plate, followed by 2 μL of test compound solution (20 mM). The plate was capped and shaken at 150 revolutions per minute for 90 minutes. At the end of the 90 minutes, the samples were filtered using the MultiScreen HTS vacuum manifold assembly and the filtrate was collected onto an acceptor plate. An aliquot (150 μL) of the filtrate from the 96-well acceptor plate above was transferred to HPLC vials and analyzed by HPLC-UV. Verapamil, ketoconazole, and reserpine were used as high, medium, and low solubility reference standards, respectively.

[0163] Pharmacokinetic analysis Male Sprague-Dawley (SD) rats aged 6-8 weeks (200-240 g) were used (n = 3, consecutive sampling). Compound 103 was formulated at 5 mg / kg in DMSO:soltol-ethanol:saline (10:10:80; v / v) for intravenous administration (IV) and at 50 mg / kg in 5% v / v NMP, 7.5% v / v solution HS-15, 50% v / v PEG-400, and 37.5% v / v TPGS (10% w / v aqueous solution) for oral administration. Plasma collection time points for IV and PO administration were 0.083, 0.25, 0.5, 1, 2, 4, 8, 24 h and 0.25, 0.5, 1, 2, 4, 8, 10, 24 h, respectively. Plasma samples were analyzed by LC-MS / MS and PK parameters were calculated with Phoenix software version 8.1.

[0164] Results and Discussion Compound 103 was found to be soluble up to 87.4 μM in PBS at pH 7.4 (Table 9). [Table 26] The plasma terminal half-life (t 1 / 2The bioavailability in mice was 1.15 h after a single intravenous injection at 5 mg / kg and 4 h after a single oral dose at 50 mg / kg. Bioavailability in rats was estimated to be 44.1% (Figure 6). EXAMPLES

[0165] The brain penetration ability of compound 103 in mice was evaluated.

[0166] Plasma and brain distribution studies Plasma and brain distribution of compound 103 was measured after a single intraperitoneal administration at 25 mg / kg and 50 mg / kg in male C57BL / 6 mice (8-12 weeks old) weighing 20-35 g. The formulation vehicle used was 5% v / v NMP, 7.5% v / v Solutol HS-15, 50% v / v PEG-400 and 37.5% v / v TPGS (10% w / v). The dose volume for intraperitoneal administration was 5 mL / kg. After blood collection, animals were sacrificed, the abdominal vena cava was incised and perfused systemically via the heart with 10 mL of saline. Brain samples were taken from sets of three mice at 0.08, 0.25, 0.5, 1, 2, 4, 8, and 10 hours. After isolation, brain samples were washed three times with ice-cold saline (each wash used ~10-20 mL saline in a disposable Petri dish for 5-10 seconds) and dried on blotting paper. Brain samples were homogenized using ice-cold phosphate-buffered saline (pH = 7.4). The total volume of homogenate was three times the tissue weight. All homogenates were stored below -70 °C until bioanalysis. Compound 103 concentrations in mouse plasma and brain samples were measured by a purpose-built LC-MS / MS method. The Non-Compartmental-Analysis tool in Phoenix WinNonlin® (version 8.0) was used for evaluation of pharmacokinetic parameters.

[0167] Results and Discussion After single intraperitoneal administration of compound 103 at 25 mg / kg and 50 mg / kg, peak plasma and brain concentrations were observed at 0.5 and 0.25 hours, respectively, suggesting rapid brain penetration. Terminal elimination half-lives were observed at 2.24 and 1.63 hours. Overall, brain concentrations were higher than plasma, with brain-Kp values ​​of 1.97 and 4.4 (Table 10).

[0168] [Table 27] EXAMPLES

[0169] Plasma and liver concentrations of Compound 103 were evaluated in mice.

[0170] Plasma and liver studies After repeated oral administration of compound 103 in 5% v / v NMP, 7.5% v / v Solutol HS-15, 50% v / v PEG-400, 37.5% v / v TPGS (10% w / v) to both 5-8 week old male (18.7-20.8 g) and female (17.6-18.9 g) C57 / BL6 mice for 14 days at 25 and 50 mg / kg / BID, plasma and liver test analytes concentrations were quantified using an AB SCIEX LC-MS / MS triple quadrupole instrument coupled with a Waters UPLC system.

[0171] Results and Discussion The liver to plasma concentration ratios in males and females were 36.03 and 85.59 at 25 mg / kg / BID and 19.57 and 31.90 at 50 mg / kg / BID (Table 11). [Table 28] EXAMPLES

[0172] The safety profile of compound 103 was evaluated by oral administration. 2-week non-GLP toxicity in mice The safety profile of compound 103 was evaluated by administering it orally to mice at 25 mg / kg and 50 mg / kg twice daily for 2 weeks. The formulation used was 5% v / v NMP, 7.5% v / v Solutol HS-15, 50% v / v PEG-400 and 37.5% v / v TPGS (10% w / v). A total of six groups of animals were used, three of which were male mice (18.7-20.8 g) and three of which were female mice (17.6-18.9 g), and the mice were 5-8 weeks old. Each group contained six mice. The animals were analyzed throughout the study and blood and tissues were analyzed at the end of the study.

[0173] Results and Discussion No abnormal clinical signs were detected and all animals survived to the end of the study. Mouse weight and weight gain were unchanged (Tables 12-13), as was food consumption (Table 14). [Table 29] [Table 30] [Table 31] [Table 32] [Table 33] [Table 34]

[0174] Hematological evaluation showed a statistically significant reduction (up to 3.4-fold) in white blood cells (WBC) in male and female mice treated with 25 mg / kg and 50 mg / kg. No other toxicologically significant changes were detected (Table 15). Furthermore, clinical chemistry evaluation showed no significant toxicological changes in any parameter in male and female mice (Table 16). Organ weights were not altered by Compound 103 (Table 17) and no obvious macroscopic pathology was observed. Histopathological analysis did not detect any differences from controls (Figure 7).

[0175] [Table 35] [Table 36] [Table 37] [Table 38] [Table 39] [Table 40]

[0176] Therefore, it can be concluded that the tolerated dose of compound 103 was > 50 mg / kg / BID when administered twice daily via oral route for 14 consecutive days to C57BL / 6 mice. EXAMPLES

[0177] K Ca 3.1 Gene knockout or selective K Ca Of the many potential clinical indications that have been experimentally validated based on 3.1 blockade, as a proof-of-concept study, we evaluated compound 103 in animal models for one clinical indication, namely stroke. K in mouse and rat models of ischemia / reperfusion stroke CaGenetic knockout or pharmacological blockade of 3.1 reduced infarct size, microglia-mediated neuroinflammation and astrogliosis, and improved neurological scores (YJ Chen et al., J. Cereb. Blood Flow Metab. 2011, 31, 2363-2374; M. Yi et al., J. Neuroinflammation 2017, 14, 203; MSV Elkind et al., Neurology 2020, 95, e1091-e1104; and Z. Yu et al., Front. Cell. Neurosci. 2017, 11, 319). Because compound 103 has excellent brain penetration, a proof-of-concept study of compound 103 in a rodent model of ischemic stroke was conducted to confirm whether compound 103 is effective in treating stroke by inhibiting neuroinflammation-mediated secondary brain injury following acute ischemia-reperfusion stroke.

[0178] MCAO ischemia-reperfusion model As a positive control, we used edaravone, a clinically approved first-in-class drug used to help patients recover after stroke.

[0179] Briefly, SD male rats weighing 240–270 g were used for MCAO studies with reperfusion for 7 days. Focal cerebral ischemia was induced by occlusion of the right middle cerebral artery (MCA). A midline incision was made in the neck to expose the right common carotid artery, internal carotid artery, and external carotid artery. A slip knot was tied on the common carotid artery, a dead knot on the proximal external carotid artery, and a slip knot on the external carotid artery near the common carotid artery bifurcation with silk thread. A small opening between the two knots on the external carotid artery was cut out, and a thread plug was inserted into the carotid artery and advanced medially to the middle cerebral artery. The plug was left in place for 60 min and then withdrawn from the vessel to restore blood supply. After 12 h of reperfusion, mice were injected intraperitoneally with 2, 5, or 10 mg / kg of compound 103 or vehicle every 12 h for 7 days. As a reference control, edaravone 5 mg / kg was administered intraperitoneally daily for 7 days. Assessment of infarct size was performed by 2,3,5-triphenyltetrazolium chloride (TTC) staining of whole brain sections (2 mm thick) starting from the frontal pole, and scanned images were analyzed with ImageJ.

[0180] Neurological behavioral assessment Animals were individually evaluated based on the scoring system described in Table 18. [Table 41]

[0181] Results and Discussion Compound 103 administered twice daily by intraperitoneal injection effectively reduced infarct volume, reducing it by nearly 50% at 10 mg / kg, more effectively than the positive control, edaravone (5 mg / kg) (Figure 8A). Neurological behavioral assessment using an 18-point system suggested that compound 103 improved neurological behavioral scores more effectively than edaravone (Figure 8B). EXAMPLES

[0182] Immunohistochemical analysis of microglial and leukocyte markers Animals were anesthetized with isoflurane (RWD Life Science), perfused with 4% PFA (Sinopharm Chemical Reagent), and fixed. Brain tissues were further immersed in 4% PFA overnight at 4 °C for 4 h, then processed in a gradient of sucrose solutions (20–30%, Sinopharm Chemical Reagent), embedded in OCT (Leica), and frozen at -80 °C. For immunofluorescence staining, brain sections from the primary somatosensory cortex (S1), primary motor cortex (M1), hippocampal CA1 area (CA1), and caudate putamen (striatum, CPu) were heated for 30 min and then washed with 0.01 M PBS (pH = 7.2–7.4, 5 min × 3). After washing, sections were blocked with 0.3% TritonX-100 (Solarbio) in 10% sheep serum (Solarbio) for 1 h at room temperature. After removing the blocking solution, brain sections were incubated with primary antibodies Iba1 (Proteintech, Cat. 10904-1-AP) and CD11b (Thermo Fisher, Cat. MA5-17857) at 4°C overnight. After three washes with 0.01M PBS (5 min each), sections were incubated with Backlight+ secondary antibody (Abcam, Cat. ab150113; Cat. ab150080) for 2 h at room temperature. After three washes, nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI, Beyotime Biotech, Cat. C1006). Images of whole brain sections were acquired by confocal laser scanning microscope (CLSM, Leica STELLARIS 5, Germany). To visualize microglia, we used two markers: Iba1, a 17 kDa EF-hand protein expressed in microglia and upregulated during microglial activation, and CD11b, the α chain of the integrin receptor CD11b / CD18 (also known as αMβ2, Mac-1, and CR3), which is highly expressed on the surface of innate immune cells, including microglia. + CD11b + The number of double positive microglia was analyzed with Image J V1.8.0. Microglia / macrophage activation is shown as the number of Iba1 and CD11b colocalized cells per section.

[0183] Results and Discussion Treatment with Compound 103 significantly reduced Iba1 expression in the CA1, CPu, M1 and S1 brain regions at day 7 compared to the MCAO or vehicle groups. + CD11b + Compound 103 significantly reduced the number of double positive microglia (Figure 9). Compound 103 reduced microglial activation of CD11b microglia when administered to rats starting 12 hours after reperfusion.

[0184] In summary, compared to other analogs in our series, compound 103 binds less to plasma proteins, has a lower cLogP value, is more soluble, accumulates to higher concentrations in the brain than in plasma after a single dose, and does not produce any unusual clinical symptoms or death when administered repeatedly at 25 and 50 mg / kg / BID daily for 14 days. Furthermore, in an exploratory proof-of-concept study, compound 103 was effective in reducing infarct volume, activating microglia, and improving neurological and behavioral scores in a rat model of ischemia / reperfusion stroke.

Claims

1. Formula (I): 【Chemistry 1】 [In the formula, R 1 H, halo, CF 3 , CN or NO 2 Selected from: R 2 and R 3 are independently H, halo, and CH 3 , C.F. 3 , CN or NO 2 Selected from: R 4 is H, halo, CN or CF 3 Selected from: R 5 and R 6 are independent, R 9a C(O)O-, R 9b OC(O)-, R 9c C(O)NRd-, R 9e R 9f NC(O)-, or the carbon atom is branched or unbranched, unsubstituted or is selected from halo and NO 2 substituted with one or more substituents selected from: R 7 and R 8 are independently H, NR 10a R 10b , OR 10c or C which is unsubstituted or substituted with one or more substituents selected from halo 1 ~C 3 alkyl; or R 5 and R 7 or R 6 and R 8 One of the pairs, together with the carbon atom to which they are attached, is carbocyclic or heterocyclic and is unsubstituted or is halo, =O, -OC(O)R 10d , -(O)COR 10e , and C 1 ~C 6 forming a 4-14 membered ring system substituted with one or more substituents selected from alkyl; R 9a ~R 9f and R 10a ~R 10e is independently H, and C which is unsubstituted or substituted with one or more substituents selected from halo. 1 ~C 6 selected from alkyl or a pharma- ceutically acceptable salt and / or solvate thereof.

2. R 1 H, F, Cl, Br, CF 3 OR NO 2 2. The compound of claim 1, selected from:

3. R 2 and R 3 are independently H, F, Cl, Br, CH 3 , C.F. 3 OR NO 2 3. A compound according to claim 1 or claim 2, or a pharma- ceutically acceptable salt and / or solvate thereof, selected from:

4. R 4 is H, F, Cl, Br, or CF 3 The compound according to any one of claims 1 to 3, selected from:

5. R 5 and R 6 is independent, R 9a C(O)O-, R 9b OC(O)-, or the carbon atoms are branched or unbranched and unsubstituted or substituted with Cl, F, and NO 2 or a pharma- ceutically acceptable salt and / or solvate thereof. The compound according to any one of claims 1 to 4, wherein the compound is selected from an alkyl ketone having 1 to 10 carbon atoms substituted with one or more substituents selected from:

6. R 7 and R 8 are independently H, or C which is unsubstituted or substituted with one or more substituents selected from F and Cl; 1 ~C 3 alkyl; or R 5 and R 7 or R 6 and R 8 One of the pairs, together with the carbon atom to which they are attached, is carbocyclic or heterocyclic and is unsubstituted or contains one of the following radicals: F, Cl, =O, and C 1 ~C 6 6. The compound according to any one of claims 1 to 5, or a pharma- ceutically acceptable salt and / or solvate thereof, which forms a 4-10 membered ring system substituted with one or more substituents selected from alkyl.

7. R 9a ~R 9f and R 10a ~R 10e are independently selected from H, and C which is unsubstituted or substituted with one or more substituents selected from F and Cl. 1 ~C 3 7. The compound according to any one of claims 1 to 6, or a pharma- ceutically acceptable salt and / or solvate thereof, wherein: R is selected from the group consisting of alkyl, aryl, aryl, arylsulfates ...

8. R 1 is H, F, Cl, or CF 3 Selected from: R 2 and R 3 are independently H, F, Cl, or CF 3 Selected from: R 4 is H, F, Cl, or CF 3 Selected from: R 5 and R 6 is independent, R 9b OC(O)-, an alkyl ketone having 1 to 3 carbon atoms, the carbon atoms being unsubstituted or substituted with one or more substituents selected from Cl and F; R 7 and R 8 is independently selected from H, or methyl that is unsubstituted or substituted with one or more substituents selected from F and Cl, or a pharma- ceutically acceptable salt and / or solvate thereof.

9. R 1 is selected from H, F, or Cl; and / or R 2 But CF 3 or in particular selected from H or F; and / or R 3 But H or CF 3 and / or R 4 is H; and / or R 5 and R 6 became independent and CH 3 OC(O)- or propan-2-onyl (e.g., R 5 and R 6 Both are CH 3 OC(O)-); and / or R 7 and R 8 are independently H and CH 3 9. The compound according to any one of claims 1 to 8, or a pharma- ceutically acceptable salt and / or solvate thereof, selected from:

10. R 7 and R 8 or a pharma- ceutically acceptable salt and / or solvate thereof. The compound of any one of claims 1 to 9, wherein at least one of is H.

11. R 7 and R 8 and R are H, or a pharma- ceutically acceptable salt and / or solvate thereof.

12. R 7 is H and R 8 CH 3 11. The compound according to any one of claims 1 to 10, which is: or a pharma- ceutically acceptable salt and / or solvate thereof.

13. R 7 and R 8 Both are CH 3 11. The compound according to any one of claims 1 to 10, which is: or a pharma- ceutically acceptable salt and / or solvate thereof.

14. R 7 CH 3 and R 8 The compound according to any one of claims 1 to 10, or a pharma- ceutically acceptable salt and / or solvate thereof, wherein

15. The list below: 【Table 1】 【Table 2】 11. The compound according to any one of claims 1 to 10, or a salt or solvate thereof, selected from:

16. The list below: 【Table 3】 【Table 4】 11. The compound according to any one of claims 1 to 10, or a salt or solvate thereof, selected from:

17. The list below: 【Table 5】 11. The compound according to any one of claims 1 to 10, or a salt or solvate thereof, selected from:

18. The list below: 【Table 6】 11. The compound according to any one of claims 1 to 10, or a salt or solvate thereof, selected from:

19. The compound is 【Chemistry 2】 11. The compound according to any one of claims 1 to 10, or a salt or solvate thereof,

20. A pharmaceutical composition comprising a compound of formula (I) as defined in any one of claims 1 to 19, or a salt or solvate thereof, in combination with a pharma- ceutically acceptable carrier, adjuvant or vehicle.

21. Use of a compound of formula (I) or a salt or solvate thereof as defined in any one of claims 1 to 19 for the manufacture of a medicament.

22. K Ca 3. Use of a compound of formula (I) as defined in any one of claims 1 to 19, or a salt or solvate thereof, for the manufacture of a medicament for the treatment or prevention of a pathology associated with an increase or altered activity of 1.

23. K Ca 3.1 is associated with an increase or altered activity in the following conditions: inflammatory bowel disease (IBD), fibrotic disease (lung, liver, kidney, heart, conjunctiva, cornea), nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), glioma (glioblastoma), lung cancer, pancreatic cancer, hepatocellular carcinoma, ovarian cancer, colorectal cancer, cystic fibrosis, diabetic kidney disease, glomerulonephritis, bone resorption, inflammatory arthritis, multiple sclerosis, atherosclerosis, restenosis after angioplasty, in-stent neoatherosclerosis, stroke, traumatic brain injury, Alzheimer's disease, hereditary sclerocytosis, sickle cell anemia, leukemia, asthma, allergic rhinitis, microglial activation, nitric oxide-dependent neurodegeneration, neuro-oncological diseases, and orphan red blood cell disorders.

23. The use according to claim 22, wherein the therapeutic agent is selected from one or more of the following:

24. K Ca 3. The use of claim 23, wherein the condition associated with an increase or altered activity of 3.1 is selected from one or more of inflammatory bowel disease (IBD), fibrotic disease (lung, liver, kidney, heart, conjunctiva, cornea), nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), glioma (glioblastoma), lung cancer, pancreatic cancer, hepatocellular carcinoma, ovarian cancer, colorectal cancer, cystic fibrosis, diabetic kidney disease, glomerulonephritis, bone resorption, inflammatory arthritis, multiple sclerosis, atherosclerosis, restenosis after angioplasty, in-stent neoatherosclerosis, stroke, traumatic brain injury, Alzheimer's disease, hereditary sicca, sickle cell anemia, leukemia, asthma, allergic rhinitis, microglial activation, and nitric oxide-dependent neurodegeneration.

25. 25. The use according to claim 23 or 24, wherein the condition is stroke.